Global Preclinical Imaging Market By Offering (Hardware, Software, Services) By Modalities, Magnetic Resonance Imaging (MRI), Molecular Imaging, Micro –CT, Pre-clinical magnetic Particle Imaging, Single Photon Emission Computed Tomography (SPECT), Ultrasound, Positron Emission Tomography (PET), Others) By Applications (Antibody-based Theranostics, Biodistribution of Radiolabeled Compounds, Drug efficacy and pharmacology, Dynamic MR contrast enhancement (DCE), Monitoring gene expression, Pharmacokinetic modelling, Labeling of Drugs and Biomarkers, Radiopharmaceutical Drug Development, Tissue Microstructure, Others) By Therapeutic Area (Oncology, Neurology, Cardiology, Inflammation, Infectious diseases, Orthopedics, Others)By End Users (Hospitals and Clinics, Biotech Companies, Research Institutes) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030

Report ID :AMI-1334 | Category : Healthcare & IT | Published Date : November, 2022 | Pages : 402 | Format :PDF

Industry Trends

Translational research is changing the way medicine is practised and how health problems are addressed. Small-animal models in fundamental and preclinical sciences are a critical component of these types of research and development techniques. The advancement of high-resolution preclinical imaging technology offers a once-in-a-lifetime opportunity to study disease in real time, quantitatively, at the molecular level, as well as the ability to evaluate illness development or response to treatment on a frequent and non-invasive basis. The greatest advantages of preclinical imaging techniques include reduced biological variability and the ability to acquire an impressive amount of unique information in continuous form without interfering with the biological process under study in distinct forms, repeated or modulated as needed, as well as a significant reduction in the number of animals required for a specific study. Furthermore, over the years molecular imaging has undergone a considerable shift. This specialised technology is gaining popularity and attention as new scanners, pharmaceutical medications, diagnostic agents, novel therapy regimens, and, ultimately, significant improvements in patient health care are being developed. Preclinical imaging technology, on the other hand, is being acknowledged as a significant tool for breaking through the bottleneck of drug development since it will likely provide excellent insights into the morphology or functionality of pharmacological models such as cell, tissue, and animal. Preclinical imaging has various advantages over traditional techniques of evaluation, including high spatiotemporal resolution, imaging sensitivity, and tissue specificity. It can also be used to determine gene expression, the metabolism of various drugs, cancer detection, medication development, and other domains. Thus with various benefits across wide therapeutic areas the global preclinical imaging market is expected to upsurge in the upcoming years.

In terms of revenue, the global preclinical imaging market was valued at US$ 910.4 Mn in 2021 growing at a CAGR of 6.2% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.

Global Preclinical Imaging Market Revenue & Forecast, (US$ Million), 2015 – 2030

Global Preclinical Imaging Market

Modalities Outlook 

Based on the modalities, positron emission tomography (PET) had the highest share in the global preclinical imaging market in year 2021. The use of positron emission tomography (PET) imaging in preclinical oncology studies has demonstrated the ability to assess the efficacy of possible new treatments. Positron emission tomography (PET) is a nuclear molecular imaging technique that is frequently combined with other imaging technologies such as magnetic resonance imaging (MRI) and computed tomography (CT) scanning to incorporate anatomical information. PET imaging is being increasingly used by researchers in the medication development phase during the last ten years because it gives data that can be converted from animal to human investigations. As breakthroughs in PET technology has powered the translation of this research into the clinical setting, small animal imaging has led to an increased understanding of illness genesis and the influence of prospective treatments. PET imaging's non-invasive, sensitive, and quantitative nature is used in preclinical pharmaceutical research to advance understanding of diseases and drug activity in the body. Multi-modal PET imaging, such as PET/MR and PET/CT, is now being used to map the path of drugs throughout the body over time, allowing researchers to monitor efficacy and determine clinical suitability, resulting in the growth of the global preclinical imaging market.

Therapeutic Area Outlook

Oncology is still a key focus for the pharmaceutical industry, and they are investing heavily in the attempt to take medicines and biologics from development to regulatory approval. Even with availability of commercial preclinical imaging systems and the ability to build relatively inexpensive custom systems, an increase in photoacoustic imaging investigation rate for various clinical applications, including and beyond cancer detection and characterization, is expected in the coming years. On the hand, neurology preclinical imaging is gaining utmost importance in the last few years by research institutes along with the leading market players that are introducing advanced MRI systems and laboratories for clinical studies. Recently Wu Tsai Neurosciences Institute officially launched the Neuroscience Preclinical Imaging Laboratory, a new shared facility for top-of-the-line magnetic resonance imaging (MRI) of model organisms. The institute aims to make brain imaging accessible throughout the neuroscience community, even to people who have never done MRI research before. Thus, these advancements across various therapeutic areas will support the growth of preclinical imaging market globally.

Region Outlook

Based on region, North America had the highest share in the preclinical imaging market in the year 2021. A well-developed research infrastructure, the availability of trained personnel, a significant number of preclinical projects, and greater adoption rates of technically advanced devices in the region are primary drivers of the market in North America. Furthermore, government activities in the region are fostering new clinical research and development projects which is supporting the growth of the preclinical imaging market in North America.

Competitive Landscape

The report provides both, qualitative and quantitative research of global preclinical imaging market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.

Some of the major players operating in the global preclinical imaging market are listed below:

  • Advanced Molecular Vision, Inc.
  • Bruker
  • Charles River Laboratories.
  • CheMatech
  • FUJIFILM
  • General Electric
  • LLC.
  • Mediso Ltd.
  • MILabs B.V.
  • MOLECUBES NV
  • MR Solutions
  • Northridge Tri-Modality Imaging, Inc.
  • PerkinElmer Inc.
  • Siemens Healthcare Private Limited
  • Other Industry Participants

Global Preclinical Imaging Market:

By Offering

  • Hardware
  • Software
  • Services

By Modalities

  • Magnetic Resonance Imaging (MRI)
  • Molecular Imaging
  • Micro –CT
  • Pre-clinical magnetic Particle Imaging
  • Single Photon Emission Computed Tomography (SPECT )
  • Ultrasound
  • Positron Emission Tomography (PET)
  • Others

By Applications 

  • Antibody-based Theranostics
  • Biodistribution of radiolabeled compounds
  • Drug efficacy and pharmacology
  • Dynamic MR contrast enhancement (DCE)
  • Monitoring gene expression
  • Pharmacokinetic modeling
  • Labeling of Drugs and Biomarkers
  • Radiopharmaceutical Drug Development
  • Tissue Microstructure
  • Others

By Therapeutic Area 

  • Oncology
  • Neurology
  • Cardiology
  • Inflammation
  • Infectious diseases
  • Orthopedics
  • Others

By End Users 

  • Hospitals and Clinics
  • Biotech Companies
  • Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Nordic Countries
      • Denmark
      • Finland
      • Iceland
      • Sweden
      • Norway
    • Benelux Union
      • Belgium
      • The Netherlands
      • Luxembourg
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • New Zealand
    • Australia
    • South Korea
    • Southeast Asia
      • Indonesia
      • Thailand
      • Malaysia
      • Singapore
      • Rest of Southeast Asia
    • Rest of Asia Pacific
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Kuwait
    • South Africa
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Argentina
    • Rest of Latin America

Table of Contents

1.    Market Scope

1.1. Market Segmentation

1.2. Years Considered

1.2.1. Historic Years: 2015 - 2020

1.2.2. Base Year: 2021

1.2.3. Forecast Years: 2022 - 2030

2.    Key Target Audiences

3.    Research Methodology

3.1. Primary Research

3.1.1. Research Questionnaire

3.1.2. Global Percentage Breakdown

3.1.3. Primary Interviews: Key Opinion Leaders (KOLs)

3.2. Secondary Research

3.2.1. Paid Databases

3.2.2. Secondary Sources

3.3. Market Size Estimates

3.3.1. Top-Down Approach

3.3.2. Bottom-Up Approach

3.4. Data Triangulation Methodology

3.5. Research Assumptions

4.    Recommendations and Insights from AMI’s Perspective**

5.    Holistic Overview of Preclinical Imaging Market

6.    Market Synopsis:  Preclinical Imaging Market

7.    Preclinical Imaging Market Analysis: Qualitative Perspective

7.1. Introduction

7.1.1. Product Definition

7.1.2. Industry Development

7.2. Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Opportunities

7.2.4. Challenges

7.3. Trends in Preclinical Imaging Market

7.4. Market Determinants Radar Chart

7.5. Macro-Economic and Micro-Economic Indicators: Preclinical Imaging Market

7.6. Impact of Covid-19 on Preclinical Imaging Market

8.    Global Preclinical Imaging Market Analysis and Forecasts, 2022 - 2030

8.1. Overview

8.1.1. Global Preclinical Imaging Market Revenue (US$ Mn)

8.2. Global Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

8.2.1. Hardware

8.2.1.1.    Definition

8.2.1.2.    Market Estimation and Penetration, 2015 - 2021

8.2.1.3.    Market Forecast, 2022 - 2030

8.2.1.4.    Compound Annual Growth Rate (CAGR)

8.2.1.5.    Regional Bifurcation

8.2.1.5.1.    North America

8.2.1.5.1.1. Market Estimation, 2015 - 2021

8.2.1.5.1.2. Market Forecast, 2022 - 2030

8.2.1.5.2.    Europe

8.2.1.5.2.1. Market Estimation, 2015 - 2021

8.2.1.5.2.2. Market Forecast, 2022 - 2030

8.2.1.5.3.    Asia Pacific

8.2.1.5.3.1. Market Estimation, 2015 - 2021

8.2.1.5.3.2. Market Forecast, 2022 - 2030

8.2.1.5.4.    Middle East and Africa

8.2.1.5.4.1. Market Estimation, 2015 - 2021

8.2.1.5.4.2. Market Forecast, 2022 - 2030

8.2.1.5.5.    Latin America

8.2.1.5.5.1. Market Estimation, 2015 - 2021

8.2.1.5.5.2. Market Forecast, 2022 - 2030

8.2.2. Software

8.2.2.1.    Definition

8.2.2.2.    Market Estimation and Penetration, 2015 - 2021

8.2.2.3.    Market Forecast, 2022 - 2030

8.2.2.4.    Compound Annual Growth Rate (CAGR)

8.2.2.5.    Regional Bifurcation

8.2.2.5.1.    North America

8.2.2.5.1.1. Market Estimation, 2015 - 2021

8.2.2.5.1.2. Market Forecast, 2022 - 2030

8.2.2.5.2.    Europe

8.2.2.5.2.1. Market Estimation, 2015 - 2021

8.2.2.5.2.2. Market Forecast, 2022 - 2030

8.2.2.5.3.    Asia Pacific

8.2.2.5.3.1. Market Estimation, 2015 - 2021

8.2.2.5.3.2. Market Forecast, 2022 - 2030

8.2.2.5.4.    Middle East and Africa

8.2.2.5.4.1. Market Estimation, 2015 - 2021

8.2.2.5.4.2. Market Forecast, 2022 - 2030

8.2.2.5.5.    Latin America

8.2.2.5.5.1. Market Estimation, 2015 - 2021

8.2.2.5.5.2. Market Forecast, 2022 - 2030

8.2.3. Services

8.2.3.1.    Definition

8.2.3.2.    Market Estimation and Penetration, 2015 - 2021

8.2.3.3.    Market Forecast, 2022 - 2030

8.2.3.4.    Compound Annual Growth Rate (CAGR)

8.2.3.5.    Regional Bifurcation

8.2.3.5.1.    North America

8.2.3.5.1.1. Market Estimation, 2015 - 2021

8.2.3.5.1.2. Market Forecast, 2022 - 2030

8.2.3.5.2.    Europe

8.2.3.5.2.1. Market Estimation, 2015 - 2021

8.2.3.5.2.2. Market Forecast, 2022 - 2030

8.2.3.5.3.    Asia Pacific

8.2.3.5.3.1. Market Estimation, 2015 - 2021

8.2.3.5.3.2. Market Forecast, 2022 - 2030

8.2.3.5.4.    Middle East and Africa

8.2.3.5.4.1. Market Estimation, 2015 - 2021

8.2.3.5.4.2. Market Forecast, 2022 - 2030

8.2.3.5.5.    Latin America

8.2.3.5.5.1. Market Estimation, 2015 - 2021

8.2.3.5.5.2. Market Forecast, 2022 - 2030

8.3. Key Segment for Channeling Investments

8.3.1. By Offering

9.    Global Preclinical Imaging Market Analysis and Forecasts, 2022 - 2030

9.1. Overview

9.2. Global Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

9.2.1. Magnetic Resonance Imaging (MRI)

9.2.1.1.    Definition

9.2.1.2.    Market Estimation and Penetration, 2015 - 2021

9.2.1.3.    Market Forecast, 2022 - 2030

9.2.1.4.    Compound Annual Growth Rate (CAGR)

9.2.1.5.    Regional Bifurcation

9.2.1.5.1.    North America

9.2.1.5.1.1. Market Estimation, 2015 - 2021

9.2.1.5.1.2. Market Forecast, 2022 - 2030

9.2.1.5.2.    Europe

9.2.1.5.2.1. Market Estimation, 2015 - 2021

9.2.1.5.2.2. Market Forecast, 2022 - 2030

9.2.1.5.3.    Asia Pacific

9.2.1.5.3.1. Market Estimation, 2015 - 2021

9.2.1.5.3.2. Market Forecast, 2022 - 2030

9.2.1.5.4.    Middle East and Africa

9.2.1.5.4.1. Market Estimation, 2015 - 2021

9.2.1.5.4.2. Market Forecast, 2022 - 2030

9.2.1.5.5.    Latin America

9.2.1.5.5.1. Market Estimation, 2015 - 2021

9.2.1.5.5.2. Market Forecast, 2022 - 2030

9.2.2. Molecular Imaging

9.2.2.1.    Definition

9.2.2.2.    Market Estimation and Penetration, 2015 - 2021

9.2.2.3.    Market Forecast, 2022 - 2030

9.2.2.4.    Compound Annual Growth Rate (CAGR)

9.2.2.5.    Regional Bifurcation

9.2.2.5.1.    North America

9.2.2.5.1.1. Market Estimation, 2015 - 2021

9.2.2.5.1.2. Market Forecast, 2022 - 2030

9.2.2.5.2.    Europe

9.2.2.5.2.1. Market Estimation, 2015 - 2021

9.2.2.5.2.2. Market Forecast, 2022 - 2030

9.2.2.5.3.    Asia Pacific

9.2.2.5.3.1. Market Estimation, 2015 - 2021

9.2.2.5.3.2. Market Forecast, 2022 - 2030

9.2.2.5.4.    Middle East and Africa

9.2.2.5.4.1. Market Estimation, 2015 - 2021

9.2.2.5.4.2. Market Forecast, 2022 - 2030

9.2.2.5.5.    Latin America

9.2.2.5.5.1. Market Estimation, 2015 - 2021

9.2.2.5.5.2. Market Forecast, 2022 - 2030

9.2.3. Micro –CT

9.2.3.1.    Definition

9.2.3.2.    Market Estimation and Penetration, 2015 - 2021

9.2.3.3.    Market Forecast, 2022 - 2030

9.2.3.4.    Compound Annual Growth Rate (CAGR)

9.2.3.5.    Regional Bifurcation

9.2.3.5.1.    North America

9.2.3.5.1.1. Market Estimation, 2015 - 2021

9.2.3.5.1.2. Market Forecast, 2022 - 2030

9.2.3.5.2.    Europe

9.2.3.5.2.1. Market Estimation, 2015 - 2021

9.2.3.5.2.2. Market Forecast, 2022 - 2030

9.2.3.5.3.    Asia Pacific

9.2.3.5.3.1. Market Estimation, 2015 - 2021

9.2.3.5.3.2. Market Forecast, 2022 - 2030

9.2.3.5.4.    Middle East and Africa

9.2.3.5.4.1. Market Estimation, 2015 - 2021

9.2.3.5.4.2. Market Forecast, 2022 - 2030

9.2.3.5.5.    Latin America

9.2.3.5.5.1. Market Estimation, 2015 - 2021

9.2.3.5.5.2. Market Forecast, 2022 - 2030

9.2.4. Pre-clinical magnetic Particle Imaging

9.2.4.1.    Definition

9.2.4.2.    Market Estimation and Penetration, 2015 - 2021

9.2.4.3.    Market Forecast, 2022 - 2030

9.2.4.4.    Compound Annual Growth Rate (CAGR)

9.2.4.5.    Regional Bifurcation

9.2.4.5.1.    North America

9.2.4.5.1.1. Market Estimation, 2015 - 2021

9.2.4.5.1.2. Market Forecast, 2022 - 2030

9.2.4.5.2.    Europe

9.2.4.5.2.1. Market Estimation, 2015 - 2021

9.2.4.5.2.2. Market Forecast, 2022 - 2030

9.2.4.5.3.    Asia Pacific

9.2.4.5.3.1. Market Estimation, 2015 - 2021

9.2.4.5.3.2. Market Forecast, 2022 - 2030

9.2.4.5.4.    Middle East and Africa

9.2.4.5.4.1. Market Estimation, 2015 - 2021

9.2.4.5.4.2. Market Forecast, 2022 - 2030

9.2.4.5.5.    Latin America

9.2.4.5.5.1. Market Estimation, 2015 - 2021

9.2.4.5.5.2. Market Forecast, 2022 - 2030

9.2.5. Single Photon Emission Computed Tomography (SPECT)

9.2.5.1.    Definition

9.2.5.2.    Market Estimation and Penetration, 2015 - 2021

9.2.5.3.    Market Forecast, 2022 - 2030

9.2.5.4.    Compound Annual Growth Rate (CAGR)

9.2.5.5.    Regional Bifurcation

9.2.5.5.1.    North America

9.2.5.5.1.1. Market Estimation, 2015 - 2021

9.2.5.5.1.2. Market Forecast, 2022 - 2030

9.2.5.5.2.    Europe

9.2.5.5.2.1. Market Estimation, 2015 - 2021

9.2.5.5.2.2. Market Forecast, 2022 - 2030

9.2.5.5.3.    Asia Pacific

9.2.5.5.3.1. Market Estimation, 2015 - 2021

9.2.5.5.3.2. Market Forecast, 2022 - 2030

9.2.5.5.4.    Middle East and Africa

9.2.5.5.4.1. Market Estimation, 2015 - 2021

9.2.5.5.4.2. Market Forecast, 2022 - 2030

9.2.5.5.5.    Latin America

9.2.5.5.5.1. Market Estimation, 2015 - 2021

9.2.5.5.5.2. Market Forecast, 2022 - 2030

9.2.6. Ultrasound

9.2.6.1.    Definition

9.2.6.2.    Market Estimation and Penetration, 2015 - 2021

9.2.6.3.    Market Forecast, 2022 - 2030

9.2.6.4.    Compound Annual Growth Rate (CAGR)

9.2.6.5.    Regional Bifurcation

9.2.6.5.1.    North America

9.2.6.5.1.1. Market Estimation, 2015 - 2021

9.2.6.5.1.2. Market Forecast, 2022 - 2030

9.2.6.5.2.    Europe

9.2.6.5.2.1. Market Estimation, 2015 - 2021

9.2.6.5.2.2. Market Forecast, 2022 - 2030

9.2.6.5.3.    Asia Pacific

9.2.6.5.3.1. Market Estimation, 2015 - 2021

9.2.6.5.3.2. Market Forecast, 2022 - 2030

9.2.6.5.4.    Middle East and Africa

9.2.6.5.4.1. Market Estimation, 2015 - 2021

9.2.6.5.4.2. Market Forecast, 2022 - 2030

9.2.6.5.5.    Latin America

9.2.6.5.5.1. Market Estimation, 2015 - 2021

9.2.6.5.5.2. Market Forecast, 2022 - 2030

9.2.7. Positron Emission Tomography (PET)

9.2.7.1.    Definition

9.2.7.2.    Market Estimation and Penetration, 2015 - 2021

9.2.7.3.    Market Forecast, 2022 - 2030

9.2.7.4.    Compound Annual Growth Rate (CAGR)

9.2.7.5.    Regional Bifurcation

9.2.7.5.1.    North America

9.2.7.5.1.1. Market Estimation, 2015 - 2021

9.2.7.5.1.2. Market Forecast, 2022 - 2030

9.2.7.5.2.    Europe

9.2.7.5.2.1. Market Estimation, 2015 - 2021

9.2.7.5.2.2. Market Forecast, 2022 - 2030

9.2.7.5.3.    Asia Pacific

9.2.7.5.3.1. Market Estimation, 2015 - 2021

9.2.7.5.3.2. Market Forecast, 2022 - 2030

9.2.7.5.4.    Middle East and Africa

9.2.7.5.4.1. Market Estimation, 2015 - 2021

9.2.7.5.4.2. Market Forecast, 2022 - 2030

9.2.7.5.5.    Latin America

9.2.7.5.5.1. Market Estimation, 2015 - 2021

9.2.7.5.5.2. Market Forecast, 2022 - 2030

9.2.8. Others

9.2.8.1.    Definition

9.2.8.2.    Market Estimation and Penetration, 2015 - 2021

9.2.8.3.    Market Forecast, 2022 - 2030

9.2.8.4.    Compound Annual Growth Rate (CAGR)

9.2.8.5.    Regional Bifurcation

9.2.8.5.1.    North America

9.2.8.5.1.1. Market Estimation, 2015 - 2021

9.2.8.5.1.2. Market Forecast, 2022 - 2030

9.2.8.5.2.    Europe

9.2.8.5.2.1. Market Estimation, 2015 - 2021

9.2.8.5.2.2. Market Forecast, 2022 - 2030

9.2.8.5.3.    Asia Pacific

9.2.8.5.3.1. Market Estimation, 2015 - 2021

9.2.8.5.3.2. Market Forecast, 2022 - 2030

9.2.8.5.4.    Middle East and Africa

9.2.8.5.4.1. Market Estimation, 2015 - 2021

9.2.8.5.4.2. Market Forecast, 2022 - 2030

9.2.8.5.5.    Latin America

9.2.8.5.5.1. Market Estimation, 2015 - 2021

9.2.8.5.5.2. Market Forecast, 2022 - 2030

9.3. Key Segment for Channeling Investments

9.3.1. By Modalities

10. Global Preclinical Imaging Market Analysis and Forecasts, 2022 - 2030

10.1. Overview

10.2. Global Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

10.2.1. Antibody-based Theranostics

10.2.1.1.  Definition

10.2.1.2.  Market Estimation and Penetration, 2015 - 2021

10.2.1.3.  Market Forecast, 2022 - 2030

10.2.1.4.  Compound Annual Growth Rate (CAGR)

10.2.1.5.  Regional Bifurcation

10.2.1.5.1.  North America

10.2.1.5.1.1. Market Estimation, 2015 - 2021

10.2.1.5.1.2. Market Forecast, 2022 - 2030

10.2.1.5.2.  Europe

10.2.1.5.2.1. Market Estimation, 2015 - 2021

10.2.1.5.2.2. Market Forecast, 2022 - 2030

10.2.1.5.3.  Asia Pacific

10.2.1.5.3.1. Market Estimation, 2015 - 2021

10.2.1.5.3.2. Market Forecast, 2022 - 2030

10.2.1.5.4.  Middle East and Africa

10.2.1.5.4.1. Market Estimation, 2015 - 2021

10.2.1.5.4.2. Market Forecast, 2022 - 2030

10.2.1.5.5.  Latin America

10.2.1.5.5.1. Market Estimation, 2015 - 2021

10.2.1.5.5.2. Market Forecast, 2022 - 2030

10.2.2. Biodistribution of radiolabeled compounds

10.2.2.1.  Definition

10.2.2.2.  Market Estimation and Penetration, 2015 - 2021

10.2.2.3.  Market Forecast, 2022 - 2030

10.2.2.4.  Compound Annual Growth Rate (CAGR)

10.2.2.5.  Regional Bifurcation

10.2.2.5.1.  North America

10.2.2.5.1.1. Market Estimation, 2015 - 2021

10.2.2.5.1.2. Market Forecast, 2022 - 2030

10.2.2.5.2.  Europe

10.2.2.5.2.1. Market Estimation, 2015 - 2021

10.2.2.5.2.2. Market Forecast, 2022 - 2030

10.2.2.5.3.  Asia Pacific

10.2.2.5.3.1. Market Estimation, 2015 - 2021

10.2.2.5.3.2. Market Forecast, 2022 - 2030

10.2.2.5.4.  Middle East and Africa

10.2.2.5.4.1. Market Estimation, 2015 - 2021

10.2.2.5.4.2. Market Forecast, 2022 - 2030

10.2.2.5.5.  Latin America

10.2.2.5.5.1. Market Estimation, 2015 - 2021

10.2.2.5.5.2. Market Forecast, 2022 - 2030

10.2.3. Drug efficacy and pharmacology

10.2.3.1.  Definition

10.2.3.2.  Market Estimation and Penetration, 2015 - 2021

10.2.3.3.  Market Forecast, 2022 - 2030

10.2.3.4.  Compound Annual Growth Rate (CAGR)

10.2.3.5.  Regional Bifurcation

10.2.3.5.1.  North America

10.2.3.5.1.1. Market Estimation, 2015 - 2021

10.2.3.5.1.2. Market Forecast, 2022 - 2030

10.2.3.5.2.  Europe

10.2.3.5.2.1. Market Estimation, 2015 - 2021

10.2.3.5.2.2. Market Forecast, 2022 - 2030

10.2.3.5.3.  Asia Pacific

10.2.3.5.3.1. Market Estimation, 2015 - 2021

10.2.3.5.3.2. Market Forecast, 2022 - 2030

10.2.3.5.4.  Middle East and Africa

10.2.3.5.4.1. Market Estimation, 2015 - 2021

10.2.3.5.4.2. Market Forecast, 2022 - 2030

10.2.3.5.5.  Latin America

10.2.3.5.5.1. Market Estimation, 2015 - 2021

10.2.3.5.5.2. Market Forecast, 2022 - 2030

10.2.4. Dynamic MR contrast enhancement (DCE)

10.2.4.1.  Definition

10.2.4.2.  Market Estimation and Penetration, 2015 - 2021

10.2.4.3.  Market Forecast, 2022 - 2030

10.2.4.4.  Compound Annual Growth Rate (CAGR)

10.2.4.5.  Regional Bifurcation

10.2.4.5.1.  North America

10.2.4.5.1.1. Market Estimation, 2015 - 2021

10.2.4.5.1.2. Market Forecast, 2022 - 2030

10.2.4.5.2.  Europe

10.2.4.5.2.1. Market Estimation, 2015 - 2021

10.2.4.5.2.2. Market Forecast, 2022 - 2030

10.2.4.5.3.  Asia Pacific

10.2.4.5.3.1. Market Estimation, 2015 - 2021

10.2.4.5.3.2. Market Forecast, 2022 - 2030

10.2.4.5.4.  Middle East and Africa

10.2.4.5.4.1. Market Estimation, 2015 - 2021

10.2.4.5.4.2. Market Forecast, 2022 - 2030

10.2.4.5.5.  Latin America

10.2.4.5.5.1. Market Estimation, 2015 - 2021

10.2.4.5.5.2. Market Forecast, 2022 - 2030

10.2.5. Monitoring gene expression

10.2.5.1.  Definition

10.2.5.2.  Market Estimation and Penetration, 2015 - 2021

10.2.5.3.  Market Forecast, 2022 - 2030

10.2.5.4.  Compound Annual Growth Rate (CAGR)

10.2.5.5.  Regional Bifurcation

10.2.5.5.1.  North America

10.2.5.5.1.1. Market Estimation, 2015 - 2021

10.2.5.5.1.2. Market Forecast, 2022 - 2030

10.2.5.5.2.  Europe

10.2.5.5.2.1. Market Estimation, 2015 - 2021

10.2.5.5.2.2. Market Forecast, 2022 - 2030

10.2.5.5.3.  Asia Pacific

10.2.5.5.3.1. Market Estimation, 2015 - 2021

10.2.5.5.3.2. Market Forecast, 2022 - 2030

10.2.5.5.4.  Middle East and Africa

10.2.5.5.4.1. Market Estimation, 2015 - 2021

10.2.5.5.4.2. Market Forecast, 2022 - 2030

10.2.5.5.5.  Latin America

10.2.5.5.5.1. Market Estimation, 2015 - 2021

10.2.5.5.5.2. Market Forecast, 2022 - 2030

10.2.6. Pharmacokinetic modeling

10.2.6.1.  Definition

10.2.6.2.  Market Estimation and Penetration, 2015 - 2021

10.2.6.3.  Market Forecast, 2022 - 2030

10.2.6.4.  Compound Annual Growth Rate (CAGR)

10.2.6.5.  Regional Bifurcation

10.2.6.5.1.  North America

10.2.6.5.1.1. Market Estimation, 2015 - 2021

10.2.6.5.1.2. Market Forecast, 2022 - 2030

10.2.6.5.2.  Europe

10.2.6.5.2.1. Market Estimation, 2015 - 2021

10.2.6.5.2.2. Market Forecast, 2022 - 2030

10.2.6.5.3.  Asia Pacific

10.2.6.5.3.1. Market Estimation, 2015 - 2021

10.2.6.5.3.2. Market Forecast, 2022 - 2030

10.2.6.5.4.  Middle East and Africa

10.2.6.5.4.1. Market Estimation, 2015 - 2021

10.2.6.5.4.2. Market Forecast, 2022 - 2030

10.2.6.5.5.  Latin America

10.2.6.5.5.1. Market Estimation, 2015 - 2021

10.2.6.5.5.2. Market Forecast, 2022 - 2030

10.2.7. Labeling of Drugs and Biomarkers

10.2.7.1.  Definition

10.2.7.2.  Market Estimation and Penetration, 2015 - 2021

10.2.7.3.  Market Forecast, 2022 - 2030

10.2.7.4.  Compound Annual Growth Rate (CAGR)

10.2.7.5.  Regional Bifurcation

10.2.7.5.1.  North America

10.2.7.5.1.1. Market Estimation, 2015 - 2021

10.2.7.5.1.2. Market Forecast, 2022 - 2030

10.2.7.5.2.  Europe

10.2.7.5.2.1. Market Estimation, 2015 - 2021

10.2.7.5.2.2. Market Forecast, 2022 - 2030

10.2.7.5.3.  Asia Pacific

10.2.7.5.3.1. Market Estimation, 2015 - 2021

10.2.7.5.3.2. Market Forecast, 2022 - 2030

10.2.7.5.4.  Middle East and Africa

10.2.7.5.4.1. Market Estimation, 2015 - 2021

10.2.7.5.4.2. Market Forecast, 2022 - 2030

10.2.7.5.5.  Latin America

10.2.7.5.5.1. Market Estimation, 2015 - 2021

10.2.7.5.5.2. Market Forecast, 2022 - 2030

10.2.8. Radiopharmaceutical Drug Development

10.2.8.1.  Definition

10.2.8.2.  Market Estimation and Penetration, 2015 - 2021

10.2.8.3.  Market Forecast, 2022 - 2030

10.2.8.4.  Compound Annual Growth Rate (CAGR)

10.2.8.5.  Regional Bifurcation

10.2.8.5.1.  North America

10.2.8.5.1.1. Market Estimation, 2015 - 2021

10.2.8.5.1.2. Market Forecast, 2022 - 2030

10.2.8.5.2.  Europe

10.2.8.5.2.1. Market Estimation, 2015 - 2021

10.2.8.5.2.2. Market Forecast, 2022 - 2030

10.2.8.5.3.  Asia Pacific

10.2.8.5.3.1. Market Estimation, 2015 - 2021

10.2.8.5.3.2. Market Forecast, 2022 - 2030

10.2.8.5.4.  Middle East and Africa

10.2.8.5.4.1. Market Estimation, 2015 - 2021

10.2.8.5.4.2. Market Forecast, 2022 - 2030

10.2.8.5.5.  Latin America

10.2.8.5.5.1. Market Estimation, 2015 - 2021

10.2.8.5.5.2. Market Forecast, 2022 - 2030

10.2.9. Tissue Microstructure

10.2.9.1.  Definition

10.2.9.2.  Market Estimation and Penetration, 2015 - 2021

10.2.9.3.  Market Forecast, 2022 - 2030

10.2.9.4.  Compound Annual Growth Rate (CAGR)

10.2.9.5.  Regional Bifurcation

10.2.9.5.1.  North America

10.2.9.5.1.1. Market Estimation, 2015 - 2021

10.2.9.5.1.2. Market Forecast, 2022 - 2030

10.2.9.5.2.  Europe

10.2.9.5.2.1. Market Estimation, 2015 - 2021

10.2.9.5.2.2. Market Forecast, 2022 - 2030

10.2.9.5.3.  Asia Pacific

10.2.9.5.3.1. Market Estimation, 2015 - 2021

10.2.9.5.3.2. Market Forecast, 2022 - 2030

10.2.9.5.4.  Middle East and Africa

10.2.9.5.4.1. Market Estimation, 2015 - 2021

10.2.9.5.4.2. Market Forecast, 2022 - 2030

10.2.9.5.5.  Latin America

10.2.9.5.5.1. Market Estimation, 2015 - 2021

10.2.9.5.5.2. Market Forecast, 2022 - 2030

10.2.10. Others

10.2.10.1.             Definition

10.2.10.2.             Market Estimation and Penetration, 2015 - 2021

10.2.10.3.             Market Forecast, 2022 - 2030

10.2.10.4.             Compound Annual Growth Rate (CAGR)

10.2.10.5.             Regional Bifurcation

10.2.10.5.1.        North America

10.2.10.5.1.1. Market Estimation, 2015 - 2021

10.2.10.5.1.2. Market Forecast, 2022 - 2030

10.2.10.5.2.        Europe

10.2.10.5.2.1. Market Estimation, 2015 - 2021

10.2.10.5.2.2. Market Forecast, 2022 - 2030

10.2.10.5.3.        Asia Pacific

10.2.10.5.3.1. Market Estimation, 2015 - 2021

10.2.10.5.3.2. Market Forecast, 2022 - 2030

10.2.10.5.4.        Middle East and Africa

10.2.10.5.4.1. Market Estimation, 2015 - 2021

10.2.10.5.4.2. Market Forecast, 2022 - 2030

10.2.10.5.5.        Latin America

10.2.10.5.5.1. Market Estimation, 2015 - 2021

10.2.10.5.5.2. Market Forecast, 2022 - 2030

10.3. Key Segment for Channeling Investments

10.3.1. By Applications

11. Global Preclinical Imaging Market Analysis and Forecasts, 2022 - 2030

11.1. Overview

11.2. Global Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

11.2.1. Oncology

11.2.1.1.  Definition

11.2.1.2.  Market Estimation and Penetration, 2015 - 2021

11.2.1.3.  Market Forecast, 2022 - 2030

11.2.1.4.  Compound Annual Growth Rate (CAGR)

11.2.1.5.  Regional Bifurcation

11.2.1.5.1.  North America

11.2.1.5.1.1. Market Estimation, 2015 - 2021

11.2.1.5.1.2. Market Forecast, 2022 - 2030

11.2.1.5.2.  Europe

11.2.1.5.2.1. Market Estimation, 2015 - 2021

11.2.1.5.2.2. Market Forecast, 2022 - 2030

11.2.1.5.3.  Asia Pacific

11.2.1.5.3.1. Market Estimation, 2015 - 2021

11.2.1.5.3.2. Market Forecast, 2022 - 2030

11.2.1.5.4.  Middle East and Africa

11.2.1.5.4.1. Market Estimation, 2015 - 2021

11.2.1.5.4.2. Market Forecast, 2022 - 2030

11.2.1.5.5.  Latin America

11.2.1.5.5.1. Market Estimation, 2015 - 2021

11.2.1.5.5.2. Market Forecast, 2022 - 2030

11.2.2. Neurology

11.2.2.1.  Definition

11.2.2.2.  Market Estimation and Penetration, 2015 - 2021

11.2.2.3.  Market Forecast, 2022 - 2030

11.2.2.4.  Compound Annual Growth Rate (CAGR)

11.2.2.5.  Regional Bifurcation

11.2.2.5.1.  North America

11.2.2.5.1.1. Market Estimation, 2015 - 2021

11.2.2.5.1.2. Market Forecast, 2022 - 2030

11.2.2.5.2.  Europe

11.2.2.5.2.1. Market Estimation, 2015 - 2021

11.2.2.5.2.2. Market Forecast, 2022 - 2030

11.2.2.5.3.  Asia Pacific

11.2.2.5.3.1. Market Estimation, 2015 - 2021

11.2.2.5.3.2. Market Forecast, 2022 - 2030

11.2.2.5.4.  Middle East and Africa

11.2.2.5.4.1. Market Estimation, 2015 - 2021

11.2.2.5.4.2. Market Forecast, 2022 - 2030

11.2.2.5.5.  Latin America

11.2.2.5.5.1. Market Estimation, 2015 - 2021

11.2.2.5.5.2. Market Forecast, 2022 - 2030

11.2.3. Cardiology

11.2.3.1.  Definition

11.2.3.2.  Market Estimation and Penetration, 2015 - 2021

11.2.3.3.  Market Forecast, 2022 - 2030

11.2.3.4.  Compound Annual Growth Rate (CAGR)

11.2.3.5.  Regional Bifurcation

11.2.3.5.1.  North America

11.2.3.5.1.1. Market Estimation, 2015 - 2021

11.2.3.5.1.2. Market Forecast, 2022 - 2030

11.2.3.5.2.  Europe

11.2.3.5.2.1. Market Estimation, 2015 - 2021

11.2.3.5.2.2. Market Forecast, 2022 - 2030

11.2.3.5.3.  Asia Pacific

11.2.3.5.3.1. Market Estimation, 2015 - 2021

11.2.3.5.3.2. Market Forecast, 2022 - 2030

11.2.3.5.4.  Middle East and Africa

11.2.3.5.4.1. Market Estimation, 2015 - 2021

11.2.3.5.4.2. Market Forecast, 2022 - 2030

11.2.3.5.5.  Latin America

11.2.3.5.5.1. Market Estimation, 2015 - 2021

11.2.3.5.5.2. Market Forecast, 2022 - 2030

11.2.4. Inflammation

11.2.4.1.  Definition

11.2.4.2.  Market Estimation and Penetration, 2015 - 2021

11.2.4.3.  Market Forecast, 2022 - 2030

11.2.4.4.  Compound Annual Growth Rate (CAGR)

11.2.4.5.  Regional Bifurcation

11.2.4.5.1.  North America

11.2.4.5.1.1. Market Estimation, 2015 - 2021

11.2.4.5.1.2. Market Forecast, 2022 - 2030

11.2.4.5.2.  Europe

11.2.4.5.2.1. Market Estimation, 2015 - 2021

11.2.4.5.2.2. Market Forecast, 2022 - 2030

11.2.4.5.3.  Asia Pacific

11.2.4.5.3.1. Market Estimation, 2015 - 2021

11.2.4.5.3.2. Market Forecast, 2022 - 2030

11.2.4.5.4.  Middle East and Africa

11.2.4.5.4.1. Market Estimation, 2015 - 2021

11.2.4.5.4.2. Market Forecast, 2022 - 2030

11.2.4.5.5.  Latin America

11.2.4.5.5.1. Market Estimation, 2015 - 2021

11.2.4.5.5.2. Market Forecast, 2022 - 2030

11.2.5. Infectious diseases

11.2.5.1.  Definition

11.2.5.2.  Market Estimation and Penetration, 2015 - 2021

11.2.5.3.  Market Forecast, 2022 - 2030

11.2.5.4.  Compound Annual Growth Rate (CAGR)

11.2.5.5.  Regional Bifurcation

11.2.5.5.1.  North America

11.2.5.5.1.1. Market Estimation, 2015 - 2021

11.2.5.5.1.2. Market Forecast, 2022 - 2030

11.2.5.5.2.  Europe

11.2.5.5.2.1. Market Estimation, 2015 - 2021

11.2.5.5.2.2. Market Forecast, 2022 - 2030

11.2.5.5.3.  Asia Pacific

11.2.5.5.3.1. Market Estimation, 2015 - 2021

11.2.5.5.3.2. Market Forecast, 2022 - 2030

11.2.5.5.4.  Middle East and Africa

11.2.5.5.4.1. Market Estimation, 2015 - 2021

11.2.5.5.4.2. Market Forecast, 2022 - 2030

11.2.5.5.5.  Latin America

11.2.5.5.5.1. Market Estimation, 2015 - 2021

11.2.5.5.5.2. Market Forecast, 2022 - 2030

11.2.6. Orthopedics

11.2.6.1.  Definition

11.2.6.2.  Market Estimation and Penetration, 2015 - 2021

11.2.6.3.  Market Forecast, 2022 - 2030

11.2.6.4.  Compound Annual Growth Rate (CAGR)

11.2.6.5.  Regional Bifurcation

11.2.6.5.1.  North America

11.2.6.5.1.1. Market Estimation, 2015 - 2021

11.2.6.5.1.2. Market Forecast, 2022 - 2030

11.2.6.5.2.  Europe

11.2.6.5.2.1. Market Estimation, 2015 - 2021

11.2.6.5.2.2. Market Forecast, 2022 - 2030

11.2.6.5.3.  Asia Pacific

11.2.6.5.3.1. Market Estimation, 2015 - 2021

11.2.6.5.3.2. Market Forecast, 2022 - 2030

11.2.6.5.4.  Middle East and Africa

11.2.6.5.4.1. Market Estimation, 2015 - 2021

11.2.6.5.4.2. Market Forecast, 2022 - 2030

11.2.6.5.5.  Latin America

11.2.6.5.5.1. Market Estimation, 2015 - 2021

11.2.6.5.5.2. Market Forecast, 2022 - 2030

11.2.7. Others

11.2.7.1.  Definition

11.2.7.2.  Market Estimation and Penetration, 2015 - 2021

11.2.7.3.  Market Forecast, 2022 - 2030

11.2.7.4.  Compound Annual Growth Rate (CAGR)

11.2.7.5.  Regional Bifurcation

11.2.7.5.1.  North America

11.2.7.5.1.1. Market Estimation, 2015 - 2021

11.2.7.5.1.2. Market Forecast, 2022 - 2030

11.2.7.5.2.  Europe

11.2.7.5.2.1. Market Estimation, 2015 - 2021

11.2.7.5.2.2. Market Forecast, 2022 - 2030

11.2.7.5.3.  Asia Pacific

11.2.7.5.3.1. Market Estimation, 2015 - 2021

11.2.7.5.3.2. Market Forecast, 2022 - 2030

11.2.7.5.4.  Middle East and Africa

11.2.7.5.4.1. Market Estimation, 2015 - 2021

11.2.7.5.4.2. Market Forecast, 2022 - 2030

11.2.7.5.5.  Latin America

11.2.7.5.5.1. Market Estimation, 2015 - 2021

11.2.7.5.5.2. Market Forecast, 2022 - 2030

11.3. Key Segment for Channeling Investments

11.3.1. By Therapeutic Area

12. Global Preclinical Imaging Market Analysis and Forecasts, 2022 - 2030

12.1. Overview

12.2. Global Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

12.2.1. Hospitals and Clinics

12.2.1.1.  Definition

12.2.1.2.  Market Estimation and Penetration, 2015 - 2021

12.2.1.3.  Market Forecast, 2022 - 2030

12.2.1.4.  Compound Annual Growth Rate (CAGR)

12.2.1.5.  Regional Bifurcation

12.2.1.5.1.  North America

12.2.1.5.1.1. Market Estimation, 2015 - 2021

12.2.1.5.1.2. Market Forecast, 2022 - 2030

12.2.1.5.2.  Europe

12.2.1.5.2.1. Market Estimation, 2015 - 2021

12.2.1.5.2.2. Market Forecast, 2022 - 2030

12.2.1.5.3.  Asia Pacific

12.2.1.5.3.1. Market Estimation, 2015 - 2021

12.2.1.5.3.2. Market Forecast, 2022 - 2030

12.2.1.5.4.  Middle East and Africa

12.2.1.5.4.1. Market Estimation, 2015 - 2021

12.2.1.5.4.2. Market Forecast, 2022 - 2030

12.2.1.5.5.  Latin America

12.2.1.5.5.1. Market Estimation, 2015 - 2021

12.2.1.5.5.2. Market Forecast, 2022 - 2030

12.2.2. Biotech Companies

12.2.2.1.  Definition

12.2.2.2.  Market Estimation and Penetration, 2015 - 2021

12.2.2.3.  Market Forecast, 2022 - 2030

12.2.2.4.  Compound Annual Growth Rate (CAGR)

12.2.2.5.  Regional Bifurcation

12.2.2.5.1.  North America

12.2.2.5.1.1. Market Estimation, 2015 - 2021

12.2.2.5.1.2. Market Forecast, 2022 - 2030

12.2.2.5.2.  Europe

12.2.2.5.2.1. Market Estimation, 2015 - 2021

12.2.2.5.2.2. Market Forecast, 2022 - 2030

12.2.2.5.3.  Asia Pacific

12.2.2.5.3.1. Market Estimation, 2015 - 2021

12.2.2.5.3.2. Market Forecast, 2022 - 2030

12.2.2.5.4.  Middle East and Africa

12.2.2.5.4.1. Market Estimation, 2015 - 2021

12.2.2.5.4.2. Market Forecast, 2022 - 2030

12.2.2.5.5.  Latin America

12.2.2.5.5.1. Market Estimation, 2015 - 2021

12.2.2.5.5.2. Market Forecast, 2022 - 2030

12.2.3. Research Institutes

12.2.3.1.  Definition

12.2.3.2.  Market Estimation and Penetration, 2015 - 2021

12.2.3.3.  Market Forecast, 2022 - 2030

12.2.3.4.  Compound Annual Growth Rate (CAGR)

12.2.3.5.  Regional Bifurcation

12.2.3.5.1.  North America

12.2.3.5.1.1. Market Estimation, 2015 - 2021

12.2.3.5.1.2. Market Forecast, 2022 - 2030

12.2.3.5.2.  Europe

12.2.3.5.2.1. Market Estimation, 2015 - 2021

12.2.3.5.2.2. Market Forecast, 2022 - 2030

12.2.3.5.3.  Asia Pacific

12.2.3.5.3.1. Market Estimation, 2015 - 2021

12.2.3.5.3.2. Market Forecast, 2022 - 2030

12.2.3.5.4.  Middle East and Africa

12.2.3.5.4.1. Market Estimation, 2015 - 2021

12.2.3.5.4.2. Market Forecast, 2022 - 2030

12.2.3.5.5.  Latin America

12.2.3.5.5.1. Market Estimation, 2015 - 2021

12.2.3.5.5.2. Market Forecast, 2022 - 2030

12.3. Key Segment for Channeling Investments

12.3.1. By End Users

13. North America Preclinical Imaging Market Analysis and Forecasts, 2022 - 2030

13.1. Overview

13.1.1. North America Preclinical Imaging Market Revenue (US$ Mn)

13.2. North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

13.2.1. Hardware

13.2.2. Software

13.2.3. Services

13.3. North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

13.3.1. Magnetic Resonance Imaging (MRI)

13.3.2. Molecular Imaging

13.3.3. Micro –CT

13.3.4. Pre-clinical magnetic Particle Imaging

13.3.5. Single Photon Emission Computed Tomography (SPECT)

13.3.6. Ultrasound

13.3.7. Positron Emission Tomography (PET)

13.3.8. Others

13.4. North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

13.4.1. Antibody-based Theranostics

13.4.2. Biodistribution of radiolabeled compounds

13.4.3. Drug efficacy and pharmacology

13.4.4. Dynamic MR contrast enhancement (DCE)

13.4.5. Monitoring gene expression

13.4.6. Pharmacokinetic modeling

13.4.7. Labeling of Drugs and Biomarkers

13.4.8. Radiopharmaceutical Drug Development

13.4.9. Tissue Microstructure

13.4.10. Others

13.5. North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

13.5.1. Oncology

13.5.2. Neurology

13.5.3. Cardiology

13.5.4. Inflammation

13.5.5. Infectious diseases

13.5.6. Orthopedics

13.5.7. Others

13.6. North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

13.6.1. Hospitals and Clinics

13.6.2. Biotech Companies

13.6.3. Research Institutes

13.7. North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country

13.7.1. U.S

13.7.1.1.  U.S Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

13.7.1.1.1.  Hardware

13.7.1.1.2.  Software

13.7.1.1.3.  Services

13.7.1.2.  U.S Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

13.7.1.2.1.  Magnetic Resonance Imaging (MRI)

13.7.1.2.2.  Molecular Imaging

13.7.1.2.3.  Micro –CT

13.7.1.2.4.  Pre-clinical magnetic Particle Imaging

13.7.1.2.5.  Single Photon Emission Computed Tomography (SPECT)

13.7.1.2.6.  Ultrasound

13.7.1.2.7.  Positron Emission Tomography (PET)

13.7.1.2.8.  Others

13.7.1.3.  U.S Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

13.7.1.3.1.  Antibody-based Theranostics

13.7.1.3.2.  Biodistribution of radiolabeled compounds

13.7.1.3.3.  Drug efficacy and pharmacology

13.7.1.3.4.  Dynamic MR contrast enhancement (DCE)

13.7.1.3.5.  Monitoring gene expression

13.7.1.3.6.  Pharmacokinetic modeling

13.7.1.3.7.  Labeling of Drugs and Biomarkers

13.7.1.3.8.  Radiopharmaceutical Drug Development

13.7.1.3.9.  Tissue Microstructure

13.7.1.3.10.        Others

13.7.1.4.  U.S Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

13.7.1.4.1.  Oncology

13.7.1.4.2.  Neurology

13.7.1.4.3.  Cardiology

13.7.1.4.4.  Inflammation

13.7.1.4.5.  Infectious diseases

13.7.1.4.6.  Orthopedics

13.7.1.4.7.  Others

13.7.1.5.  U.S Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

13.7.1.5.1.  Hospitals and Clinics

13.7.1.5.2.  Biotech Companies

13.7.1.5.3.  Research Institutes

13.7.2. Canada

13.7.2.1.  Canada Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

13.7.2.1.1.  Hardware

13.7.2.1.2.  Software

13.7.2.1.3.  Services

13.7.2.2.  Canada Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

13.7.2.2.1.  Magnetic Resonance Imaging (MRI)

13.7.2.2.2.  Molecular Imaging

13.7.2.2.3.  Micro –CT

13.7.2.2.4.  Pre-clinical magnetic Particle Imaging

13.7.2.2.5.  Single Photon Emission Computed Tomography (SPECT)

13.7.2.2.6.  Ultrasound

13.7.2.2.7.  Positron Emission Tomography (PET)

13.7.2.2.8.  Others

13.7.2.3.  Canada Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

13.7.2.3.1.  Antibody-based Theranostics

13.7.2.3.2.  Biodistribution of radiolabeled compounds

13.7.2.3.3.  Drug efficacy and pharmacology

13.7.2.3.4.  Dynamic MR contrast enhancement (DCE)

13.7.2.3.5.  Monitoring gene expression

13.7.2.3.6.  Pharmacokinetic modeling

13.7.2.3.7.  Labeling of Drugs and Biomarkers

13.7.2.3.8.  Radiopharmaceutical Drug Development

13.7.2.3.9.  Tissue Microstructure

13.7.2.3.10.        Others

13.7.2.4.  Canada Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

13.7.2.4.1.  Oncology

13.7.2.4.2.  Neurology

13.7.2.4.3.  Cardiology

13.7.2.4.4.  Inflammation

13.7.2.4.5.  Infectious diseases

13.7.2.4.6.  Orthopedics

13.7.2.4.7.  Others

13.7.2.5.  Canada Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

13.7.2.5.1.  Hospitals and Clinics

13.7.2.5.2.  Biotech Companies

13.7.2.5.3.  Research Institutes

13.7.3. Mexico

13.7.3.1.  Mexico Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

13.7.3.1.1.  Hardware

13.7.3.1.2.  Software

13.7.3.1.3.  Services

13.7.3.2.  Mexico Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

13.7.3.2.1.  Magnetic Resonance Imaging (MRI)

13.7.3.2.2.  Molecular Imaging

13.7.3.2.3.  Micro –CT

13.7.3.2.4.  Pre-clinical magnetic Particle Imaging

13.7.3.2.5.  Single Photon Emission Computed Tomography (SPECT)

13.7.3.2.6.  Ultrasound

13.7.3.2.7.  Positron Emission Tomography (PET)

13.7.3.2.8.  Others

13.7.3.3.  Mexico Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

13.7.3.3.1.  Antibody-based Theranostics

13.7.3.3.2.  Biodistribution of radiolabeled compounds

13.7.3.3.3.  Drug efficacy and pharmacology

13.7.3.3.4.  Dynamic MR contrast enhancement (DCE)

13.7.3.3.5.  Monitoring gene expression

13.7.3.3.6.  Pharmacokinetic modeling

13.7.3.3.7.  Labeling of Drugs and Biomarkers

13.7.3.3.8.  Radiopharmaceutical Drug Development

13.7.3.3.9.  Tissue Microstructure

13.7.3.3.10.        Others

13.7.3.4.  Mexico Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

13.7.3.4.1.  Oncology

13.7.3.4.2.  Neurology

13.7.3.4.3.  Cardiology

13.7.3.4.4.  Inflammation

13.7.3.4.5.  Infectious diseases

13.7.3.4.6.  Orthopedics

13.7.3.4.7.  Others

13.7.3.5.  Mexico Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

13.7.3.5.1.  Hospitals and Clinics

13.7.3.5.2.  Biotech Companies

13.7.3.5.3.  Research Institutes

13.7.4. Rest of North America

13.7.4.1.  Rest of North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

13.7.4.1.1.  Hardware

13.7.4.1.2.  Software

13.7.4.1.3.  Services

13.7.4.2.  Rest of North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

13.7.4.2.1.  Magnetic Resonance Imaging (MRI)

13.7.4.2.2.  Molecular Imaging

13.7.4.2.3.  Micro –CT

13.7.4.2.4.  Pre-clinical magnetic Particle Imaging

13.7.4.2.5.  Single Photon Emission Computed Tomography (SPECT)

13.7.4.2.6.  Ultrasound

13.7.4.2.7.  Positron Emission Tomography (PET)

13.7.4.2.8.  Others

13.7.4.3.  Rest of North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

13.7.4.3.1.  Antibody-based Theranostics

13.7.4.3.2.  Biodistribution of radiolabeled compounds

13.7.4.3.3.  Drug efficacy and pharmacology

13.7.4.3.4.  Dynamic MR contrast enhancement (DCE)

13.7.4.3.5.  Monitoring gene expression

13.7.4.3.6.  Pharmacokinetic modeling

13.7.4.3.7.  Labeling of Drugs and Biomarkers

13.7.4.3.8.  Radiopharmaceutical Drug Development

13.7.4.3.9.  Tissue Microstructure

13.7.4.3.10.        Others

13.7.4.4.  Rest of North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

13.7.4.4.1.  Oncology

13.7.4.4.2.  Neurology

13.7.4.4.3.  Cardiology

13.7.4.4.4.  Inflammation

13.7.4.4.5.  Infectious diseases

13.7.4.4.6.  Orthopedics

13.7.4.4.7.  Others

13.7.4.5.  Rest of North America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

13.7.4.5.1.  Hospitals and Clinics

13.7.4.5.2.  Biotech Companies

13.7.4.5.3.  Research Institutes

13.8. Key Segment for Channeling Investments

13.8.1. By Country

13.8.2. By Offering

13.8.3. By Modalities

13.8.4. By Applications

13.8.5. By Therapeutic Area

13.8.6. By End Users

14. Europe Preclinical Imaging Market Analysis and Forecasts, 2022 - 2030

14.1. Overview

14.1.1. Europe Preclinical Imaging Market Revenue (US$ Mn)

14.2. Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

14.2.1. Hardware

14.2.2. Software

14.2.3. Services

14.3. Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

14.3.1. Magnetic Resonance Imaging (MRI)

14.3.2. Molecular Imaging

14.3.3. Micro –CT

14.3.4. Pre-clinical magnetic Particle Imaging

14.3.5. Single Photon Emission Computed Tomography (SPECT)

14.3.6. Ultrasound

14.3.7. Positron Emission Tomography (PET)

14.3.8. Others

14.4. Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

14.4.1. Antibody-based Theranostics

14.4.2. Biodistribution of radiolabeled compounds

14.4.3. Drug efficacy and pharmacology

14.4.4. Dynamic MR contrast enhancement (DCE)

14.4.5. Monitoring gene expression

14.4.6. Pharmacokinetic modeling

14.4.7. Labeling of Drugs and Biomarkers

14.4.8. Radiopharmaceutical Drug Development

14.4.9. Tissue Microstructure

14.4.10. Others

14.5. Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.5.1. Oncology

14.5.2. Neurology

14.5.3. Cardiology

14.5.4. Inflammation

14.5.5. Infectious diseases

14.5.6. Orthopedics

14.5.7. Others

14.6. Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

14.6.1. Hospitals and Clinics

14.6.2. Biotech Companies

14.6.3. Research Institutes

14.7. Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country

14.7.1. France

14.7.1.1.  France Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

14.7.1.1.1.  Hardware

14.7.1.1.2.  Software

14.7.1.1.3.  Services

14.7.1.2.  France Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

14.7.1.2.1.  Magnetic Resonance Imaging (MRI)

14.7.1.2.2.  Molecular Imaging

14.7.1.2.3.  Micro –CT

14.7.1.2.4.  Pre-clinical magnetic Particle Imaging

14.7.1.2.5.  Single Photon Emission Computed Tomography (SPECT)

14.7.1.2.6.  Ultrasound

14.7.1.2.7.  Positron Emission Tomography (PET)

14.7.1.2.8.  Others

14.7.1.3.  France Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

14.7.1.3.1.  Antibody-based Theranostics

14.7.1.3.2.  Biodistribution of radiolabeled compounds

14.7.1.3.3.  Drug efficacy and pharmacology

14.7.1.3.4.  Dynamic MR contrast enhancement (DCE)

14.7.1.3.5.  Monitoring gene expression

14.7.1.3.6.  Pharmacokinetic modeling

14.7.1.3.7.  Labeling of Drugs and Biomarkers

14.7.1.3.8.  Radiopharmaceutical Drug Development

14.7.1.3.9.  Tissue Microstructure

14.7.1.3.10.        Others

14.7.1.4.  France Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.7.1.4.1.  Oncology

14.7.1.4.2.  Neurology

14.7.1.4.3.  Cardiology

14.7.1.4.4.  Inflammation

14.7.1.4.5.  Infectious diseases

14.7.1.4.6.  Orthopedics

14.7.1.4.7.  Others

14.7.1.5.  France Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

14.7.1.5.1.  Hospitals and Clinics

14.7.1.5.2.  Biotech Companies

14.7.1.5.3.  Research Institutes

14.7.2. The UK

14.7.2.1.  The UK Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

14.7.2.1.1.  Hardware

14.7.2.1.2.  Software

14.7.2.1.3.  Services

14.7.2.2.  The UK Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

14.7.2.2.1.  Magnetic Resonance Imaging (MRI)

14.7.2.2.2.  Molecular Imaging

14.7.2.2.3.  Micro –CT

14.7.2.2.4.  Pre-clinical magnetic Particle Imaging

14.7.2.2.5.  Single Photon Emission Computed Tomography (SPECT)

14.7.2.2.6.  Ultrasound

14.7.2.2.7.  Positron Emission Tomography (PET)

14.7.2.2.8.  Others

14.7.2.3.  The UK Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

14.7.2.3.1.  Antibody-based Theranostics

14.7.2.3.2.  Biodistribution of radiolabeled compounds

14.7.2.3.3.  Drug efficacy and pharmacology

14.7.2.3.4.  Dynamic MR contrast enhancement (DCE)

14.7.2.3.5.  Monitoring gene expression

14.7.2.3.6.  Pharmacokinetic modeling

14.7.2.3.7.  Labeling of Drugs and Biomarkers

14.7.2.3.8.  Radiopharmaceutical Drug Development

14.7.2.3.9.  Tissue Microstructure

14.7.2.3.10.        Others

14.7.2.4.  The UK Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.7.2.4.1.  Oncology

14.7.2.4.2.  Neurology

14.7.2.4.3.  Cardiology

14.7.2.4.4.  Inflammation

14.7.2.4.5.  Infectious diseases

14.7.2.4.6.  Orthopedics

14.7.2.4.7.  Others

14.7.2.5.  The UK Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

14.7.2.5.1.  Hospitals and Clinics

14.7.2.5.2.  Biotech Companies

14.7.2.5.3.  Research Institutes

14.7.3. Spain

14.7.3.1.  Spain Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

14.7.3.1.1.  Hardware

14.7.3.1.2.  Software

14.7.3.1.3.  Services

14.7.3.2.  Spain Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

14.7.3.2.1.  Magnetic Resonance Imaging (MRI)

14.7.3.2.2.  Molecular Imaging

14.7.3.2.3.  Micro –CT

14.7.3.2.4.  Pre-clinical magnetic Particle Imaging

14.7.3.2.5.  Single Photon Emission Computed Tomography (SPECT)

14.7.3.2.6.  Ultrasound

14.7.3.2.7.  Positron Emission Tomography (PET)

14.7.3.2.8.  Others

14.7.3.3.  Spain Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

14.7.3.3.1.  Antibody-based Theranostics

14.7.3.3.2.  Biodistribution of radiolabeled compounds

14.7.3.3.3.  Drug efficacy and pharmacology

14.7.3.3.4.  Dynamic MR contrast enhancement (DCE)

14.7.3.3.5.  Monitoring gene expression

14.7.3.3.6.  Pharmacokinetic modeling

14.7.3.3.7.  Labeling of Drugs and Biomarkers

14.7.3.3.8.  Radiopharmaceutical Drug Development

14.7.3.3.9.  Tissue Microstructure

14.7.3.3.10.        Others

14.7.3.4.  Spain Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.7.3.4.1.  Oncology

14.7.3.4.2.  Neurology

14.7.3.4.3.  Cardiology

14.7.3.4.4.  Inflammation

14.7.3.4.5.  Infectious diseases

14.7.3.4.6.  Orthopedics

14.7.3.4.7.  Others

14.7.3.5.  Spain Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

14.7.3.5.1.  Hospitals and Clinics

14.7.3.5.2.  Biotech Companies

14.7.3.5.3.  Research Institutes

14.7.4. Germany

14.7.4.1.  Germany Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

14.7.4.1.1.  Hardware

14.7.4.1.2.  Software

14.7.4.1.3.  Services

14.7.4.2.  Germany Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

14.7.4.2.1.  Magnetic Resonance Imaging (MRI)

14.7.4.2.2.  Molecular Imaging

14.7.4.2.3.  Micro –CT

14.7.4.2.4.  Pre-clinical magnetic Particle Imaging

14.7.4.2.5.  Single Photon Emission Computed Tomography (SPECT)

14.7.4.2.6.  Ultrasound

14.7.4.2.7.  Positron Emission Tomography (PET)

14.7.4.2.8.  Others

14.7.4.3.  Germany Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

14.7.4.3.1.  Antibody-based Theranostics

14.7.4.3.2.  Biodistribution of radiolabeled compounds

14.7.4.3.3.  Drug efficacy and pharmacology

14.7.4.3.4.  Dynamic MR contrast enhancement (DCE)

14.7.4.3.5.  Monitoring gene expression

14.7.4.3.6.  Pharmacokinetic modeling

14.7.4.3.7.  Labeling of Drugs and Biomarkers

14.7.4.3.8.  Radiopharmaceutical Drug Development

14.7.4.3.9.  Tissue Microstructure

14.7.4.3.10.        Others

14.7.4.4.  Germany Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.7.4.4.1.  Oncology

14.7.4.4.2.  Neurology

14.7.4.4.3.  Cardiology

14.7.4.4.4.  Inflammation

14.7.4.4.5.  Infectious diseases

14.7.4.4.6.  Orthopedics

14.7.4.4.7.  Others

14.7.4.5.  Germany Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

14.7.4.5.1.  Hospitals and Clinics

14.7.4.5.2.  Biotech Companies

14.7.4.5.3.  Research Institutes

14.7.5. Italy

14.7.5.1.  Italy Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

14.7.5.1.1.  Hardware

14.7.5.1.2.  Software

14.7.5.1.3.  Services

14.7.5.2.  Italy Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

14.7.5.2.1.  Magnetic Resonance Imaging (MRI)

14.7.5.2.2.  Molecular Imaging

14.7.5.2.3.  Micro –CT

14.7.5.2.4.  Pre-clinical magnetic Particle Imaging

14.7.5.2.5.  Single Photon Emission Computed Tomography (SPECT)

14.7.5.2.6.  Ultrasound

14.7.5.2.7.  Positron Emission Tomography (PET)

14.7.5.2.8.  Others

14.7.5.3.  Italy Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

14.7.5.3.1.  Antibody-based Theranostics

14.7.5.3.2.  Biodistribution of radiolabeled compounds

14.7.5.3.3.  Drug efficacy and pharmacology

14.7.5.3.4.  Dynamic MR contrast enhancement (DCE)

14.7.5.3.5.  Monitoring gene expression

14.7.5.3.6.  Pharmacokinetic modeling

14.7.5.3.7.  Labeling of Drugs and Biomarkers

14.7.5.3.8.  Radiopharmaceutical Drug Development

14.7.5.3.9.  Tissue Microstructure

14.7.5.3.10.        Others

14.7.5.4.  Italy Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.7.5.4.1.  Oncology

14.7.5.4.2.  Neurology

14.7.5.4.3.  Cardiology

14.7.5.4.4.  Inflammation

14.7.5.4.5.  Infectious diseases

14.7.5.4.6.  Orthopedics

14.7.5.4.7.  Others

14.7.5.5.  Italy Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

14.7.5.5.1.  Hospitals and Clinics

14.7.5.5.2.  Biotech Companies

14.7.5.5.3.  Research Institutes

14.7.6. Nordic Countries

14.7.6.1.  Nordic Countries Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

14.7.6.1.1.  Hardware

14.7.6.1.2.  Software

14.7.6.1.3.  Services

14.7.6.2.  Nordic Countries Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

14.7.6.2.1.  Magnetic Resonance Imaging (MRI)

14.7.6.2.2.  Molecular Imaging

14.7.6.2.3.  Micro –CT

14.7.6.2.4.  Pre-clinical magnetic Particle Imaging

14.7.6.2.5.  Single Photon Emission Computed Tomography (SPECT)

14.7.6.2.6.  Ultrasound

14.7.6.2.7.  Positron Emission Tomography (PET)

14.7.6.2.8.  Others

14.7.6.3.  Nordic Countries Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

14.7.6.3.1.  Antibody-based Theranostics

14.7.6.3.2.  Biodistribution of radiolabeled compounds

14.7.6.3.3.  Drug efficacy and pharmacology

14.7.6.3.4.  Dynamic MR contrast enhancement (DCE)

14.7.6.3.5.  Monitoring gene expression

14.7.6.3.6.  Pharmacokinetic modeling

14.7.6.3.7.  Labeling of Drugs and Biomarkers

14.7.6.3.8.  Radiopharmaceutical Drug Development

14.7.6.3.9.  Tissue Microstructure

14.7.6.3.10.        Others

14.7.6.4.  Nordic Countries Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.7.6.4.1.  Oncology

14.7.6.4.2.  Neurology

14.7.6.4.3.  Cardiology

14.7.6.4.4.  Inflammation

14.7.6.4.5.  Infectious diseases

14.7.6.4.6.  Orthopedics

14.7.6.4.7.  Others

14.7.6.5.  Nordic Countries Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

14.7.6.5.1.  Hospitals and Clinics

14.7.6.5.2.  Biotech Companies

14.7.6.5.3.  Research Institutes

14.7.6.6.  Nordic Countries Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country

14.7.6.6.1.  Denmark

14.7.6.6.2.  Finland

14.7.6.6.3.  Iceland

14.7.6.6.4.  Sweden

14.7.6.6.5.  Norway

14.7.7. Benelux Union

14.7.7.1.  Benelux Union Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

14.7.7.1.1.  Hardware

14.7.7.1.2.  Software

14.7.7.1.3.  Services

14.7.7.2.  Benelux Union Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

14.7.7.2.1.  Magnetic Resonance Imaging (MRI)

14.7.7.2.2.  Molecular Imaging

14.7.7.2.3.  Micro –CT

14.7.7.2.4.  Pre-clinical magnetic Particle Imaging

14.7.7.2.5.  Single Photon Emission Computed Tomography (SPECT)

14.7.7.2.6.  Ultrasound

14.7.7.2.7.  Positron Emission Tomography (PET)

14.7.7.2.8.  Others

14.7.7.3.  Benelux Union Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

14.7.7.3.1.  Antibody-based Theranostics

14.7.7.3.2.  Biodistribution of radiolabeled compounds

14.7.7.3.3.  Drug efficacy and pharmacology

14.7.7.3.4.  Dynamic MR contrast enhancement (DCE)

14.7.7.3.5.  Monitoring gene expression

14.7.7.3.6.  Pharmacokinetic modeling

14.7.7.3.7.  Labeling of Drugs and Biomarkers

14.7.7.3.8.  Radiopharmaceutical Drug Development

14.7.7.3.9.  Tissue Microstructure

14.7.7.3.10.        Others

14.7.7.4.  Benelux Union Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.7.7.4.1.  Oncology

14.7.7.4.2.  Neurology

14.7.7.4.3.  Cardiology

14.7.7.4.4.  Inflammation

14.7.7.4.5.  Infectious diseases

14.7.7.4.6.  Orthopedics

14.7.7.4.7.  Others

14.7.7.5.  Benelux Union Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

14.7.7.5.1.  Hospitals and Clinics

14.7.7.5.2.  Biotech Companies

14.7.7.5.3.  Research Institutes

14.7.7.6.  Benelux Union Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country

14.7.7.6.1.  Belgium

14.7.7.6.2.  The Netherlands

14.7.7.6.3.  Luxembourg

14.7.8. Rest of Europe

14.7.8.1.  Rest of Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

14.7.8.1.1.  Hardware

14.7.8.1.2.  Software

14.7.8.1.3.  Services

14.7.8.2.  Rest of Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

14.7.8.2.1.  Magnetic Resonance Imaging (MRI)

14.7.8.2.2.  Molecular Imaging

14.7.8.2.3.  Micro –CT

14.7.8.2.4.  Pre-clinical magnetic Particle Imaging

14.7.8.2.5.  Single Photon Emission Computed Tomography (SPECT)

14.7.8.2.6.  Ultrasound

14.7.8.2.7.  Positron Emission Tomography (PET)

14.7.8.2.8.  Others

14.7.8.3.  Rest of Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

14.7.8.3.1.  Antibody-based Theranostics

14.7.8.3.2.  Biodistribution of radiolabeled compounds

14.7.8.3.3.  Drug efficacy and pharmacology

14.7.8.3.4.  Dynamic MR contrast enhancement (DCE)

14.7.8.3.5.  Monitoring gene expression

14.7.8.3.6.  Pharmacokinetic modeling

14.7.8.3.7.  Labeling of Drugs and Biomarkers

14.7.8.3.8.  Radiopharmaceutical Drug Development

14.7.8.3.9.  Tissue Microstructure

14.7.8.3.10.        Others

14.7.8.4.  Rest of Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

14.7.8.4.1.  Oncology

14.7.8.4.2.  Neurology

14.7.8.4.3.  Cardiology

14.7.8.4.4.  Inflammation

14.7.8.4.5.  Infectious diseases

14.7.8.4.6.  Orthopedics

14.7.8.4.7.  Others

14.7.8.5.  Rest of Europe Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

14.7.8.5.1.  Hospitals and Clinics

14.7.8.5.2.  Biotech Companies

14.7.8.5.3.  Research Institutes

14.8. Key Segment for Channeling Investments

14.8.1. By Country

14.8.2. By Offering

14.8.3. By Modalities

14.8.4. By Applications

14.8.5. By Therapeutic Area

14.8.6. By End Users

15. Asia Pacific Preclinical Imaging Market Analysis and Forecasts, 2022 - 2030

15.1. Overview

15.1.1. Asia Pacific Preclinical Imaging Market Revenue (US$ Mn)

15.2. Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

15.2.1. Hardware

15.2.2. Software

15.2.3. Services

15.3. Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

15.3.1. Magnetic Resonance Imaging (MRI)

15.3.2. Molecular Imaging

15.3.3. Micro –CT

15.3.4. Pre-clinical magnetic Particle Imaging

15.3.5. Single Photon Emission Computed Tomography (SPECT)

15.3.6. Ultrasound

15.3.7. Positron Emission Tomography (PET)

15.3.8. Others

15.4. Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

15.4.1. Antibody-based Theranostics

15.4.2. Biodistribution of radiolabeled compounds

15.4.3. Drug efficacy and pharmacology

15.4.4. Dynamic MR contrast enhancement (DCE)

15.4.5. Monitoring gene expression

15.4.6. Pharmacokinetic modeling

15.4.7. Labeling of Drugs and Biomarkers

15.4.8. Radiopharmaceutical Drug Development

15.4.9. Tissue Microstructure

15.4.10. Others

15.5. Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.5.1. Oncology

15.5.2. Neurology

15.5.3. Cardiology

15.5.4. Inflammation

15.5.5. Infectious diseases

15.5.6. Orthopedics

15.5.7. Others

15.6. Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

15.6.1. Hospitals and Clinics

15.6.2. Biotech Companies

15.6.3. Research Institutes

15.7. Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country

15.7.1. China

15.7.1.1.  China Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

15.7.1.1.1.  Hardware

15.7.1.1.2.  Software

15.7.1.1.3.  Services

15.7.1.2.  China Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

15.7.1.2.1.  Magnetic Resonance Imaging (MRI)

15.7.1.2.2.  Molecular Imaging

15.7.1.2.3.  Micro –CT

15.7.1.2.4.  Pre-clinical magnetic Particle Imaging

15.7.1.2.5.  Single Photon Emission Computed Tomography (SPECT)

15.7.1.2.6.  Ultrasound

15.7.1.2.7.  Positron Emission Tomography (PET)

15.7.1.2.8.  Others

15.7.1.3.  China Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

15.7.1.3.1.  Antibody-based Theranostics

15.7.1.3.2.  Biodistribution of radiolabeled compounds

15.7.1.3.3.  Drug efficacy and pharmacology

15.7.1.3.4.  Dynamic MR contrast enhancement (DCE)

15.7.1.3.5.  Monitoring gene expression

15.7.1.3.6.  Pharmacokinetic modeling

15.7.1.3.7.  Labeling of Drugs and Biomarkers

15.7.1.3.8.  Radiopharmaceutical Drug Development

15.7.1.3.9.  Tissue Microstructure

15.7.1.3.10.        Others

15.7.1.4.  China Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.7.1.4.1.  Oncology

15.7.1.4.2.  Neurology

15.7.1.4.3.  Cardiology

15.7.1.4.4.  Inflammation

15.7.1.4.5.  Infectious diseases

15.7.1.4.6.  Orthopedics

15.7.1.4.7.  Others

15.7.1.5.  China Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

15.7.1.5.1.  Hospitals and Clinics

15.7.1.5.2.  Biotech Companies

15.7.1.5.3.  Research Institutes

15.7.2. Japan

15.7.2.1.  Japan Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

15.7.2.1.1.  Hardware

15.7.2.1.2.  Software

15.7.2.1.3.  Services

15.7.2.2.  Japan Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

15.7.2.2.1.  Magnetic Resonance Imaging (MRI)

15.7.2.2.2.  Molecular Imaging

15.7.2.2.3.  Micro –CT

15.7.2.2.4.  Pre-clinical magnetic Particle Imaging

15.7.2.2.5.  Single Photon Emission Computed Tomography (SPECT)

15.7.2.2.6.  Ultrasound

15.7.2.2.7.  Positron Emission Tomography (PET)

15.7.2.2.8.  Others

15.7.2.3.  Japan Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

15.7.2.3.1.  Antibody-based Theranostics

15.7.2.3.2.  Biodistribution of radiolabeled compounds

15.7.2.3.3.  Drug efficacy and pharmacology

15.7.2.3.4.  Dynamic MR contrast enhancement (DCE)

15.7.2.3.5.  Monitoring gene expression

15.7.2.3.6.  Pharmacokinetic modeling

15.7.2.3.7.  Labeling of Drugs and Biomarkers

15.7.2.3.8.  Radiopharmaceutical Drug Development

15.7.2.3.9.  Tissue Microstructure

15.7.2.3.10.        Others

15.7.2.4.  Japan Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.7.2.4.1.  Oncology

15.7.2.4.2.  Neurology

15.7.2.4.3.  Cardiology

15.7.2.4.4.  Inflammation

15.7.2.4.5.  Infectious diseases

15.7.2.4.6.  Orthopedics

15.7.2.4.7.  Others

15.7.2.5.  Japan Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

15.7.2.5.1.  Hospitals and Clinics

15.7.2.5.2.  Biotech Companies

15.7.2.5.3.  Research Institutes

15.7.3. India

15.7.3.1.  India Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

15.7.3.1.1.  Hardware

15.7.3.1.2.  Software

15.7.3.1.3.  Services

15.7.3.2.  India Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

15.7.3.2.1.  Magnetic Resonance Imaging (MRI)

15.7.3.2.2.  Molecular Imaging

15.7.3.2.3.  Micro –CT

15.7.3.2.4.  Pre-clinical magnetic Particle Imaging

15.7.3.2.5.  Single Photon Emission Computed Tomography (SPECT)

15.7.3.2.6.  Ultrasound

15.7.3.2.7.  Positron Emission Tomography (PET)

15.7.3.2.8.  Others

15.7.3.3.  India Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

15.7.3.3.1.  Antibody-based Theranostics

15.7.3.3.2.  Biodistribution of radiolabeled compounds

15.7.3.3.3.  Drug efficacy and pharmacology

15.7.3.3.4.  Dynamic MR contrast enhancement (DCE)

15.7.3.3.5.  Monitoring gene expression

15.7.3.3.6.  Pharmacokinetic modeling

15.7.3.3.7.  Labeling of Drugs and Biomarkers

15.7.3.3.8.  Radiopharmaceutical Drug Development

15.7.3.3.9.  Tissue Microstructure

15.7.3.3.10.        Others

15.7.3.4.  India Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.7.3.4.1.  Oncology

15.7.3.4.2.  Neurology

15.7.3.4.3.  Cardiology

15.7.3.4.4.  Inflammation

15.7.3.4.5.  Infectious diseases

15.7.3.4.6.  Orthopedics

15.7.3.4.7.  Others

15.7.3.5.  India Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

15.7.3.5.1.  Hospitals and Clinics

15.7.3.5.2.  Biotech Companies

15.7.3.5.3.  Research Institutes

15.7.4. New Zealand

15.7.4.1.  New Zealand Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

15.7.4.1.1.  Hardware

15.7.4.1.2.  Software

15.7.4.1.3.  Services

15.7.4.2.  New Zealand Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

15.7.4.2.1.  Magnetic Resonance Imaging (MRI)

15.7.4.2.2.  Molecular Imaging

15.7.4.2.3.  Micro –CT

15.7.4.2.4.  Pre-clinical magnetic Particle Imaging

15.7.4.2.5.  Single Photon Emission Computed Tomography (SPECT)

15.7.4.2.6.  Ultrasound

15.7.4.2.7.  Positron Emission Tomography (PET)

15.7.4.2.8.  Others

15.7.4.3.  New Zealand Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

15.7.4.3.1.  Antibody-based Theranostics

15.7.4.3.2.  Biodistribution of radiolabeled compounds

15.7.4.3.3.  Drug efficacy and pharmacology

15.7.4.3.4.  Dynamic MR contrast enhancement (DCE)

15.7.4.3.5.  Monitoring gene expression

15.7.4.3.6.  Pharmacokinetic modeling

15.7.4.3.7.  Labeling of Drugs and Biomarkers

15.7.4.3.8.  Radiopharmaceutical Drug Development

15.7.4.3.9.  Tissue Microstructure

15.7.4.3.10.        Others

15.7.4.4.  New Zealand Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.7.4.4.1.  Oncology

15.7.4.4.2.  Neurology

15.7.4.4.3.  Cardiology

15.7.4.4.4.  Inflammation

15.7.4.4.5.  Infectious diseases

15.7.4.4.6.  Orthopedics

15.7.4.4.7.  Others

15.7.4.5.  New Zealand Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

15.7.4.5.1.  Hospitals and Clinics

15.7.4.5.2.  Biotech Companies

15.7.4.5.3.  Research Institutes

15.7.5. Australia

15.7.5.1.  Australia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

15.7.5.1.1.  Hardware

15.7.5.1.2.  Software

15.7.5.1.3.  Services

15.7.5.2.  Australia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

15.7.5.2.1.  Magnetic Resonance Imaging (MRI)

15.7.5.2.2.  Molecular Imaging

15.7.5.2.3.  Micro –CT

15.7.5.2.4.  Pre-clinical magnetic Particle Imaging

15.7.5.2.5.  Single Photon Emission Computed Tomography (SPECT)

15.7.5.2.6.  Ultrasound

15.7.5.2.7.  Positron Emission Tomography (PET)

15.7.5.2.8.  Others

15.7.5.3.  Australia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

15.7.5.3.1.  Antibody-based Theranostics

15.7.5.3.2.  Biodistribution of radiolabeled compounds

15.7.5.3.3.  Drug efficacy and pharmacology

15.7.5.3.4.  Dynamic MR contrast enhancement (DCE)

15.7.5.3.5.  Monitoring gene expression

15.7.5.3.6.  Pharmacokinetic modeling

15.7.5.3.7.  Labeling of Drugs and Biomarkers

15.7.5.3.8.  Radiopharmaceutical Drug Development

15.7.5.3.9.  Tissue Microstructure

15.7.5.3.10.        Others

15.7.5.4.  Australia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.7.5.4.1.  Oncology

15.7.5.4.2.  Neurology

15.7.5.4.3.  Cardiology

15.7.5.4.4.  Inflammation

15.7.5.4.5.  Infectious diseases

15.7.5.4.6.  Orthopedics

15.7.5.4.7.  Others

15.7.5.5.  Australia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

15.7.5.5.1.  Hospitals and Clinics

15.7.5.5.2.  Biotech Companies

15.7.5.5.3.  Research Institutes

15.7.6. South Korea

15.7.6.1.  South Korea Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

15.7.6.1.1.  Hardware

15.7.6.1.2.  Software

15.7.6.1.3.  Services

15.7.6.2.  South Korea Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

15.7.6.2.1.  Magnetic Resonance Imaging (MRI)

15.7.6.2.2.  Molecular Imaging

15.7.6.2.3.  Micro –CT

15.7.6.2.4.  Pre-clinical magnetic Particle Imaging

15.7.6.2.5.  Single Photon Emission Computed Tomography (SPECT)

15.7.6.2.6.  Ultrasound

15.7.6.2.7.  Positron Emission Tomography (PET)

15.7.6.2.8.  Others

15.7.6.3.  South Korea Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

15.7.6.3.1.  Antibody-based Theranostics

15.7.6.3.2.  Biodistribution of radiolabeled compounds

15.7.6.3.3.  Drug efficacy and pharmacology

15.7.6.3.4.  Dynamic MR contrast enhancement (DCE)

15.7.6.3.5.  Monitoring gene expression

15.7.6.3.6.  Pharmacokinetic modeling

15.7.6.3.7.  Labeling of Drugs and Biomarkers

15.7.6.3.8.  Radiopharmaceutical Drug Development

15.7.6.3.9.  Tissue Microstructure

15.7.6.3.10.        Others

15.7.6.4.  South Korea Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.7.6.4.1.  Oncology

15.7.6.4.2.  Neurology

15.7.6.4.3.  Cardiology

15.7.6.4.4.  Inflammation

15.7.6.4.5.  Infectious diseases

15.7.6.4.6.  Orthopedics

15.7.6.4.7.  Others

15.7.6.5.  South Korea Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

15.7.6.5.1.  Hospitals and Clinics

15.7.6.5.2.  Biotech Companies

15.7.6.5.3.  Research Institutes

15.7.7. Southeast Asia

15.7.7.1.  Southeast Asia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

15.7.7.1.1.  Hardware

15.7.7.1.2.  Software

15.7.7.1.3.  Services

15.7.7.2.  Southeast Asia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

15.7.7.2.1.  Magnetic Resonance Imaging (MRI)

15.7.7.2.2.  Molecular Imaging

15.7.7.2.3.  Micro –CT

15.7.7.2.4.  Pre-clinical magnetic Particle Imaging

15.7.7.2.5.  Single Photon Emission Computed Tomography (SPECT)

15.7.7.2.6.  Ultrasound

15.7.7.2.7.  Positron Emission Tomography (PET)

15.7.7.2.8.  Others

15.7.7.3.  Southeast Asia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

15.7.7.3.1.  Antibody-based Theranostics

15.7.7.3.2.  Biodistribution of radiolabeled compounds

15.7.7.3.3.  Drug efficacy and pharmacology

15.7.7.3.4.  Dynamic MR contrast enhancement (DCE)

15.7.7.3.5.  Monitoring gene expression

15.7.7.3.6.  Pharmacokinetic modeling

15.7.7.3.7.  Labeling of Drugs and Biomarkers

15.7.7.3.8.  Radiopharmaceutical Drug Development

15.7.7.3.9.  Tissue Microstructure

15.7.7.3.10.        Others

15.7.7.4.  Southeast Asia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.7.7.4.1.  Oncology

15.7.7.4.2.  Neurology

15.7.7.4.3.  Cardiology

15.7.7.4.4.  Inflammation

15.7.7.4.5.  Infectious diseases

15.7.7.4.6.  Orthopedics

15.7.7.4.7.  Others

15.7.7.5.  Southeast Asia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

15.7.7.5.1.  Hospitals and Clinics

15.7.7.5.2.  Biotech Companies

15.7.7.5.3.  Research Institutes

15.7.7.6.  Southeast Asia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country

15.7.7.6.1.  Indonesia

15.7.7.6.2.  Thailand

15.7.7.6.3.  Malaysia

15.7.7.6.4.  Singapore

15.7.7.6.5.  Rest of Southeast Asia

15.7.8. Rest of Asia Pacific

15.7.8.1.  Rest of Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

15.7.8.1.1.  Hardware

15.7.8.1.2.  Software

15.7.8.1.3.  Services

15.7.8.2.  Rest of Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

15.7.8.2.1.  Magnetic Resonance Imaging (MRI)

15.7.8.2.2.  Molecular Imaging

15.7.8.2.3.  Micro –CT

15.7.8.2.4.  Pre-clinical magnetic Particle Imaging

15.7.8.2.5.  Single Photon Emission Computed Tomography (SPECT)

15.7.8.2.6.  Ultrasound

15.7.8.2.7.  Positron Emission Tomography (PET)

15.7.8.2.8.  Others

15.7.8.3.  Rest of Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

15.7.8.3.1.  Antibody-based Theranostics

15.7.8.3.2.  Biodistribution of radiolabeled compounds

15.7.8.3.3.  Drug efficacy and pharmacology

15.7.8.3.4.  Dynamic MR contrast enhancement (DCE)

15.7.8.3.5.  Monitoring gene expression

15.7.8.3.6.  Pharmacokinetic modeling

15.7.8.3.7.  Labeling of Drugs and Biomarkers

15.7.8.3.8.  Radiopharmaceutical Drug Development

15.7.8.3.9.  Tissue Microstructure

15.7.8.3.10.        Others

15.7.8.4.  Rest of Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

15.7.8.4.1.  Oncology

15.7.8.4.2.  Neurology

15.7.8.4.3.  Cardiology

15.7.8.4.4.  Inflammation

15.7.8.4.5.  Infectious diseases

15.7.8.4.6.  Orthopedics

15.7.8.4.7.  Others

15.7.8.5.  Rest of Asia Pacific Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

15.7.8.5.1.  Hospitals and Clinics

15.7.8.5.2.  Biotech Companies

15.7.8.5.3.  Research Institutes

15.8. Key Segment for Channeling Investments

15.8.1. By Country

15.8.2. By Offering

15.8.3. By Modalities

15.8.4. By Applications

15.8.5. By Therapeutic Area

15.8.6. By End Users

16. Middle East and Africa Preclinical Imaging Market Analysis and Forecasts, 2022 - 2030

16.1. Overview

16.1.1. Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn)

16.2. Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

16.2.1. Hardware

16.2.2. Software

16.2.3. Services

16.3. Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

16.3.1. Magnetic Resonance Imaging (MRI)

16.3.2. Molecular Imaging

16.3.3. Micro –CT

16.3.4. Pre-clinical magnetic Particle Imaging

16.3.5. Single Photon Emission Computed Tomography (SPECT)

16.3.6. Ultrasound

16.3.7. Positron Emission Tomography (PET)

16.3.8. Others

16.4. Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

16.4.1. Antibody-based Theranostics

16.4.2. Biodistribution of radiolabeled compounds

16.4.3. Drug efficacy and pharmacology

16.4.4. Dynamic MR contrast enhancement (DCE)

16.4.5. Monitoring gene expression

16.4.6. Pharmacokinetic modeling

16.4.7. Labeling of Drugs and Biomarkers

16.4.8. Radiopharmaceutical Drug Development

16.4.9. Tissue Microstructure

16.4.10. Others

16.5. Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.5.1. Oncology

16.5.2. Neurology

16.5.3. Cardiology

16.5.4. Inflammation

16.5.5. Infectious diseases

16.5.6. Orthopedics

16.5.7. Others

16.6. Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

16.6.1. Hospitals and Clinics

16.6.2. Biotech Companies

16.6.3. Research Institutes

16.7. Middle East and Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country

16.7.1. Saudi Arabia

16.7.1.1.  Saudi Arabia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

16.7.1.1.1.  Hardware

16.7.1.1.2.  Software

16.7.1.1.3.  Services

16.7.1.2.  Saudi Arabia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

16.7.1.2.1.  Magnetic Resonance Imaging (MRI)

16.7.1.2.2.  Molecular Imaging

16.7.1.2.3.  Micro –CT

16.7.1.2.4.  Pre-clinical magnetic Particle Imaging

16.7.1.2.5.  Single Photon Emission Computed Tomography (SPECT)

16.7.1.2.6.  Ultrasound

16.7.1.2.7.  Positron Emission Tomography (PET)

16.7.1.2.8.  Others

16.7.1.3.  Saudi Arabia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

16.7.1.3.1.  Antibody-based Theranostics

16.7.1.3.2.  Biodistribution of radiolabeled compounds

16.7.1.3.3.  Drug efficacy and pharmacology

16.7.1.3.4.  Dynamic MR contrast enhancement (DCE)

16.7.1.3.5.  Monitoring gene expression

16.7.1.3.6.  Pharmacokinetic modeling

16.7.1.3.7.  Labeling of Drugs and Biomarkers

16.7.1.3.8.  Radiopharmaceutical Drug Development

16.7.1.3.9.  Tissue Microstructure

16.7.1.3.10.        Others

16.7.1.4.  Saudi Arabia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.7.1.4.1.  Oncology

16.7.1.4.2.  Neurology

16.7.1.4.3.  Cardiology

16.7.1.4.4.  Inflammation

16.7.1.4.5.  Infectious diseases

16.7.1.4.6.  Orthopedics

16.7.1.4.7.  Others

16.7.1.5.  Saudi Arabia Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

16.7.1.5.1.  Hospitals and Clinics

16.7.1.5.2.  Biotech Companies

16.7.1.5.3.  Research Institutes

16.7.2. UAE

16.7.2.1.  UAE Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

16.7.2.1.1.  Hardware

16.7.2.1.2.  Software

16.7.2.1.3.  Services

16.7.2.2.  UAE Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

16.7.2.2.1.  Magnetic Resonance Imaging (MRI)

16.7.2.2.2.  Molecular Imaging

16.7.2.2.3.  Micro –CT

16.7.2.2.4.  Pre-clinical magnetic Particle Imaging

16.7.2.2.5.  Single Photon Emission Computed Tomography (SPECT)

16.7.2.2.6.  Ultrasound

16.7.2.2.7.  Positron Emission Tomography (PET)

16.7.2.2.8.  Others

16.7.2.3.  UAE Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

16.7.2.3.1.  Antibody-based Theranostics

16.7.2.3.2.  Biodistribution of radiolabeled compounds

16.7.2.3.3.  Drug efficacy and pharmacology

16.7.2.3.4.  Dynamic MR contrast enhancement (DCE)

16.7.2.3.5.  Monitoring gene expression

16.7.2.3.6.  Pharmacokinetic modeling

16.7.2.3.7.  Labeling of Drugs and Biomarkers

16.7.2.3.8.  Radiopharmaceutical Drug Development

16.7.2.3.9.  Tissue Microstructure

16.7.2.3.10.        Others

16.7.2.4.  UAE Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.7.2.4.1.  Oncology

16.7.2.4.2.  Neurology

16.7.2.4.3.  Cardiology

16.7.2.4.4.  Inflammation

16.7.2.4.5.  Infectious diseases

16.7.2.4.6.  Orthopedics

16.7.2.4.7.  Others

16.7.2.5.  UAE Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

16.7.2.5.1.  Hospitals and Clinics

16.7.2.5.2.  Biotech Companies

16.7.2.5.3.  Research Institutes

16.7.3. Egypt

16.7.3.1.  Egypt Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

16.7.3.1.1.  Hardware

16.7.3.1.2.  Software

16.7.3.1.3.  Services

16.7.3.2.  Egypt Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

16.7.3.2.1.  Magnetic Resonance Imaging (MRI)

16.7.3.2.2.  Molecular Imaging

16.7.3.2.3.  Micro –CT

16.7.3.2.4.  Pre-clinical magnetic Particle Imaging

16.7.3.2.5.  Single Photon Emission Computed Tomography (SPECT)

16.7.3.2.6.  Ultrasound

16.7.3.2.7.  Positron Emission Tomography (PET)

16.7.3.2.8.  Others

16.7.3.3.  Egypt Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

16.7.3.3.1.  Antibody-based Theranostics

16.7.3.3.2.  Biodistribution of radiolabeled compounds

16.7.3.3.3.  Drug efficacy and pharmacology

16.7.3.3.4.  Dynamic MR contrast enhancement (DCE)

16.7.3.3.5.  Monitoring gene expression

16.7.3.3.6.  Pharmacokinetic modeling

16.7.3.3.7.  Labeling of Drugs and Biomarkers

16.7.3.3.8.  Radiopharmaceutical Drug Development

16.7.3.3.9.  Tissue Microstructure

16.7.3.3.10.        Others

16.7.3.4.  Egypt Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.7.3.4.1.  Oncology

16.7.3.4.2.  Neurology

16.7.3.4.3.  Cardiology

16.7.3.4.4.  Inflammation

16.7.3.4.5.  Infectious diseases

16.7.3.4.6.  Orthopedics

16.7.3.4.7.  Others

16.7.3.5.  Egypt Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

16.7.3.5.1.  Hospitals and Clinics

16.7.3.5.2.  Biotech Companies

16.7.3.5.3.  Research Institutes

16.7.4. Kuwait

16.7.4.1.  Kuwait Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

16.7.4.1.1.  Hardware

16.7.4.1.2.  Software

16.7.4.1.3.  Services

16.7.4.2.  Kuwait Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

16.7.4.2.1.  Magnetic Resonance Imaging (MRI)

16.7.4.2.2.  Molecular Imaging

16.7.4.2.3.  Micro –CT

16.7.4.2.4.  Pre-clinical magnetic Particle Imaging

16.7.4.2.5.  Single Photon Emission Computed Tomography (SPECT)

16.7.4.2.6.  Ultrasound

16.7.4.2.7.  Positron Emission Tomography (PET)

16.7.4.2.8.  Others

16.7.4.3.  Kuwait Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

16.7.4.3.1.  Antibody-based Theranostics

16.7.4.3.2.  Biodistribution of radiolabeled compounds

16.7.4.3.3.  Drug efficacy and pharmacology

16.7.4.3.4.  Dynamic MR contrast enhancement (DCE)

16.7.4.3.5.  Monitoring gene expression

16.7.4.3.6.  Pharmacokinetic modeling

16.7.4.3.7.  Labeling of Drugs and Biomarkers

16.7.4.3.8.  Radiopharmaceutical Drug Development

16.7.4.3.9.  Tissue Microstructure

16.7.4.3.10.        Others

16.7.4.4.  Kuwait Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.7.4.4.1.  Oncology

16.7.4.4.2.  Neurology

16.7.4.4.3.  Cardiology

16.7.4.4.4.  Inflammation

16.7.4.4.5.  Infectious diseases

16.7.4.4.6.  Orthopedics

16.7.4.4.7.  Others

16.7.4.5.  Kuwait Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

16.7.4.5.1.  Hospitals and Clinics

16.7.4.5.2.  Biotech Companies

16.7.4.5.3.  Research Institutes

16.7.5. South Africa

16.7.5.1.  South Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

16.7.5.1.1.  Hardware

16.7.5.1.2.  Software

16.7.5.1.3.  Services

16.7.5.2.  South Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

16.7.5.2.1.  Magnetic Resonance Imaging (MRI)

16.7.5.2.2.  Molecular Imaging

16.7.5.2.3.  Micro –CT

16.7.5.2.4.  Pre-clinical magnetic Particle Imaging

16.7.5.2.5.  Single Photon Emission Computed Tomography (SPECT)

16.7.5.2.6.  Ultrasound

16.7.5.2.7.  Positron Emission Tomography (PET)

16.7.5.2.8.  Others

16.7.5.3.  South Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

16.7.5.3.1.  Antibody-based Theranostics

16.7.5.3.2.  Biodistribution of radiolabeled compounds

16.7.5.3.3.  Drug efficacy and pharmacology

16.7.5.3.4.  Dynamic MR contrast enhancement (DCE)

16.7.5.3.5.  Monitoring gene expression

16.7.5.3.6.  Pharmacokinetic modeling

16.7.5.3.7.  Labeling of Drugs and Biomarkers

16.7.5.3.8.  Radiopharmaceutical Drug Development

16.7.5.3.9.  Tissue Microstructure

16.7.5.3.10.        Others

16.7.5.4.  South Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.7.5.4.1.  Oncology

16.7.5.4.2.  Neurology

16.7.5.4.3.  Cardiology

16.7.5.4.4.  Inflammation

16.7.5.4.5.  Infectious diseases

16.7.5.4.6.  Orthopedics

16.7.5.4.7.  Others

16.7.5.5.  South Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

16.7.5.5.1.  Hospitals and Clinics

16.7.5.5.2.  Biotech Companies

16.7.5.5.3.  Research Institutes

16.7.6. Rest of Middle East & Africa

16.7.6.1.  Rest of Middle East & Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

16.7.6.1.1.  Hardware

16.7.6.1.2.  Software

16.7.6.1.3.  Services

16.7.6.2.  Rest of Middle East & Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

16.7.6.2.1.  Magnetic Resonance Imaging (MRI)

16.7.6.2.2.  Molecular Imaging

16.7.6.2.3.  Micro –CT

16.7.6.2.4.  Pre-clinical magnetic Particle Imaging

16.7.6.2.5.  Single Photon Emission Computed Tomography (SPECT)

16.7.6.2.6.  Ultrasound

16.7.6.2.7.  Positron Emission Tomography (PET)

16.7.6.2.8.  Others

16.7.6.3.  Rest of Middle East & Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

16.7.6.3.1.  Antibody-based Theranostics

16.7.6.3.2.  Biodistribution of radiolabeled compounds

16.7.6.3.3.  Drug efficacy and pharmacology

16.7.6.3.4.  Dynamic MR contrast enhancement (DCE)

16.7.6.3.5.  Monitoring gene expression

16.7.6.3.6.  Pharmacokinetic modeling

16.7.6.3.7.  Labeling of Drugs and Biomarkers

16.7.6.3.8.  Radiopharmaceutical Drug Development

16.7.6.3.9.  Tissue Microstructure

16.7.6.3.10.        Others

16.7.6.4.  Rest of Middle East & Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

16.7.6.4.1.  Oncology

16.7.6.4.2.  Neurology

16.7.6.4.3.  Cardiology

16.7.6.4.4.  Inflammation

16.7.6.4.5.  Infectious diseases

16.7.6.4.6.  Orthopedics

16.7.6.4.7.  Others

16.7.6.5.  Rest of Middle East & Africa Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

16.7.6.5.1.  Hospitals and Clinics

16.7.6.5.2.  Biotech Companies

16.7.6.5.3.  Research Institutes

16.8. Key Segment for Channeling Investments

16.8.1. By Country

16.8.2. By Offering

16.8.3. By Modalities

16.8.4. By Applications

16.8.5. By Therapeutic Area

16.8.6. By End Users

17. Latin America Preclinical Imaging Market Analysis and Forecasts, 2022 - 2030

17.1. Overview

17.1.1. Latin America Preclinical Imaging Market Revenue (US$ Mn)

17.2. Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

17.2.1. Hardware

17.2.2. Software

17.2.3. Services

17.3. Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

17.3.1. Magnetic Resonance Imaging (MRI)

17.3.2. Molecular Imaging

17.3.3. Micro –CT

17.3.4. Pre-clinical magnetic Particle Imaging

17.3.5. Single Photon Emission Computed Tomography (SPECT)

17.3.6. Ultrasound

17.3.7. Positron Emission Tomography (PET)

17.3.8. Others

17.4. Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

17.4.1. Antibody-based Theranostics

17.4.2. Biodistribution of radiolabeled compounds

17.4.3. Drug efficacy and pharmacology

17.4.4. Dynamic MR contrast enhancement (DCE)

17.4.5. Monitoring gene expression

17.4.6. Pharmacokinetic modeling

17.4.7. Labeling of Drugs and Biomarkers

17.4.8. Radiopharmaceutical Drug Development

17.4.9. Tissue Microstructure

17.4.10. Others

17.5. Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

17.5.1. Oncology

17.5.2. Neurology

17.5.3. Cardiology

17.5.4. Inflammation

17.5.5. Infectious diseases

17.5.6. Orthopedics

17.5.7. Others

17.6. Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

17.6.1. Hospitals and Clinics

17.6.2. Biotech Companies

17.6.3. Research Institutes

17.7. Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Country

17.7.1. Brazil

17.7.1.1.  Brazil Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

17.7.1.1.1.  Hardware

17.7.1.1.2.  Software

17.7.1.1.3.  Services

17.7.1.2.  Brazil Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

17.7.1.2.1.  Magnetic Resonance Imaging (MRI)

17.7.1.2.2.  Molecular Imaging

17.7.1.2.3.  Micro –CT

17.7.1.2.4.  Pre-clinical magnetic Particle Imaging

17.7.1.2.5.  Single Photon Emission Computed Tomography (SPECT)

17.7.1.2.6.  Ultrasound

17.7.1.2.7.  Positron Emission Tomography (PET)

17.7.1.2.8.  Others

17.7.1.3.  Brazil Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

17.7.1.3.1.  Antibody-based Theranostics

17.7.1.3.2.  Biodistribution of radiolabeled compounds

17.7.1.3.3.  Drug efficacy and pharmacology

17.7.1.3.4.  Dynamic MR contrast enhancement (DCE)

17.7.1.3.5.  Monitoring gene expression

17.7.1.3.6.  Pharmacokinetic modeling

17.7.1.3.7.  Labeling of Drugs and Biomarkers

17.7.1.3.8.  Radiopharmaceutical Drug Development

17.7.1.3.9.  Tissue Microstructure

17.7.1.3.10.        Others

17.7.1.4.  Brazil Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

17.7.1.4.1.  Oncology

17.7.1.4.2.  Neurology

17.7.1.4.3.  Cardiology

17.7.1.4.4.  Inflammation

17.7.1.4.5.  Infectious diseases

17.7.1.4.6.  Orthopedics

17.7.1.4.7.  Others

17.7.1.5.  Brazil Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

17.7.1.5.1.  Hospitals and Clinics

17.7.1.5.2.  Biotech Companies

17.7.1.5.3.  Research Institutes

17.7.2. Argentina

17.7.2.1.  Argentina Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

17.7.2.1.1.  Hardware

17.7.2.1.2.  Software

17.7.2.1.3.  Services

17.7.2.2.  Argentina Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

17.7.2.2.1.  Magnetic Resonance Imaging (MRI)

17.7.2.2.2.  Molecular Imaging

17.7.2.2.3.  Micro –CT

17.7.2.2.4.  Pre-clinical magnetic Particle Imaging

17.7.2.2.5.  Single Photon Emission Computed Tomography (SPECT)

17.7.2.2.6.  Ultrasound

17.7.2.2.7.  Positron Emission Tomography (PET)

17.7.2.2.8.  Others

17.7.2.3.  Argentina Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

17.7.2.3.1.  Antibody-based Theranostics

17.7.2.3.2.  Biodistribution of radiolabeled compounds

17.7.2.3.3.  Drug efficacy and pharmacology

17.7.2.3.4.  Dynamic MR contrast enhancement (DCE)

17.7.2.3.5.  Monitoring gene expression

17.7.2.3.6.  Pharmacokinetic modeling

17.7.2.3.7.  Labeling of Drugs and Biomarkers

17.7.2.3.8.  Radiopharmaceutical Drug Development

17.7.2.3.9.  Tissue Microstructure

17.7.2.3.10.        Others

17.7.2.4.  Argentina Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

17.7.2.4.1.  Oncology

17.7.2.4.2.  Neurology

17.7.2.4.3.  Cardiology

17.7.2.4.4.  Inflammation

17.7.2.4.5.  Infectious diseases

17.7.2.4.6.  Orthopedics

17.7.2.4.7.  Others

17.7.2.5.  Argentina Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

17.7.2.5.1.  Hospitals and Clinics

17.7.2.5.2.  Biotech Companies

17.7.2.5.3.  Research Institutes

17.7.3. Rest of Latin America

17.7.3.1.  Rest of Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Offering

17.7.3.1.1.  Hardware

17.7.3.1.2.  Software

17.7.3.1.3.  Services

17.7.3.2.  Rest of Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Modalities

17.7.3.2.1.  Magnetic Resonance Imaging (MRI)

17.7.3.2.2.  Molecular Imaging

17.7.3.2.3.  Micro –CT

17.7.3.2.4.  Pre-clinical magnetic Particle Imaging

17.7.3.2.5.  Single Photon Emission Computed Tomography (SPECT)

17.7.3.2.6.  Ultrasound

17.7.3.2.7.  Positron Emission Tomography (PET)

17.7.3.2.8.  Others

17.7.3.3.  Rest of Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Applications

17.7.3.3.1.  Antibody-based Theranostics

17.7.3.3.2.  Biodistribution of radiolabeled compounds

17.7.3.3.3.  Drug efficacy and pharmacology

17.7.3.3.4.  Dynamic MR contrast enhancement (DCE)

17.7.3.3.5.  Monitoring gene expression

17.7.3.3.6.  Pharmacokinetic modeling

17.7.3.3.7.  Labeling of Drugs and Biomarkers

17.7.3.3.8.  Radiopharmaceutical Drug Development

17.7.3.3.9.  Tissue Microstructure

17.7.3.3.10.        Others

17.7.3.4.  Rest of Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area

17.7.3.4.1.  Oncology

17.7.3.4.2.  Neurology

17.7.3.4.3.  Cardiology

17.7.3.4.4.  Inflammation

17.7.3.4.5.  Infectious diseases

17.7.3.4.6.  Orthopedics

17.7.3.4.7.  Others

17.7.3.5.  Rest of Latin America Preclinical Imaging Market Revenue (US$ Mn) and Forecasts, By End Users

17.7.3.5.1.  Hospitals and Clinics

17.7.3.5.2.  Biotech Companies

17.7.3.5.3.  Research Institutes

17.8. Key Segment for Channeling Investments

17.8.1. By Country

17.8.2. By Offering

17.8.3. By Modalities

17.8.4. By Applications

17.8.5. By Therapeutic Area

17.8.6. By End Users

18. Competitive Benchmarking

18.1. Brand Benchmarking

18.2. Market Share Analysis, 2021

18.3. Global Presence and Growth Strategies

18.3.1. Mergers and Acquisitions

18.3.2. Product Launches

18.3.3. Investments Trends

18.3.4. R&D Initiatives

19. Player Profiles

19.1. Advanced Molecular Vision, Inc.

19.1.1. Company Details

19.1.2. Company Overview

19.1.3. Product Offerings

19.1.4. Key Developments

19.1.5. Financial Analysis

19.1.6. SWOT Analysis

19.1.7. Business Strategies

19.2. Bruker

19.2.1. Company Details

19.2.2. Company Overview

19.2.3. Product Offerings

19.2.4. Key Developments

19.2.5. Financial Analysis

19.2.6. SWOT Analysis

19.2.7. Business Strategies

19.3. Charles River Laboratories.

19.3.1. Company Details

19.3.2. Company Overview

19.3.3. Product Offerings

19.3.4. Key Developments

19.3.5. Financial Analysis

19.3.6. SWOT Analysis

19.3.7. Business Strategies

19.4. CheMatech

19.4.1. Company Details

19.4.2. Company Overview

19.4.3. Product Offerings

19.4.4. Key Developments

19.4.5. Financial Analysis

19.4.6. SWOT Analysis

19.4.7. Business Strategies

19.5. FUJIFILM

19.5.1. Company Details

19.5.2. Company Overview

19.5.3. Product Offerings

19.5.4. Key Developments

19.5.5. Financial Analysis

19.5.6. SWOT Analysis

19.5.7. Business Strategies

19.6. General Electric

19.6.1. Company Details

19.6.2. Company Overview

19.6.3. Product Offerings

19.6.4. Key Developments

19.6.5. Financial Analysis

19.6.6. SWOT Analysis

19.6.7. Business Strategies

19.7. Invicro. LLC.

19.7.1. Company Details

19.7.2. Company Overview

19.7.3. Product Offerings

19.7.4. Key Developments

19.7.5. Financial Analysis

19.7.6. SWOT Analysis

19.7.7. Business Strategies

19.8. Mediso Ltd.

19.8.1. Company Details

19.8.2. Company Overview

19.8.3. Product Offerings

19.8.4. Key Developments

19.8.5. Financial Analysis

19.8.6. SWOT Analysis

19.8.7. Business Strategies

19.9. MILabs B.V.

19.9.1. Company Details

19.9.2. Company Overview

19.9.3. Product Offerings

19.9.4. Key Developments

19.9.5. Financial Analysis

19.9.6. SWOT Analysis

19.9.7. Business Strategies

19.10. MOLECUBES NV

19.10.1. Company Details

19.10.2. Company Overview

19.10.3. Product Offerings

19.10.4. Key Developments

19.10.5. Financial Analysis

19.10.6. SWOT Analysis

19.10.7. Business Strategies

19.11. MR Solutions

19.11.1. Company Details

19.11.2. Company Overview

19.11.3. Product Offerings

19.11.4. Key Developments

19.11.5. Financial Analysis

19.11.6. SWOT Analysis

19.11.7. Business Strategies

19.12. Northridge Tri-Modality Imaging, Inc.

19.12.1. Company Details

19.12.2. Company Overview

19.12.3. Product Offerings

19.12.4. Key Developments

19.12.5. Financial Analysis

19.12.6. SWOT Analysis

19.12.7. Business Strategies

19.13. PerkinElmer Inc.

19.13.1. Company Details

19.13.2. Company Overview

19.13.3. Product Offerings

19.13.4. Key Developments

19.13.5. Financial Analysis

19.13.6. SWOT Analysis

19.13.7. Business Strategies

19.14. Siemens Healthcare Private Limited

19.14.1. Company Details

19.14.2. Company Overview

19.14.3. Product Offerings

19.14.4. Key Developments

19.14.5. Financial Analysis

19.14.6. SWOT Analysis

19.14.7. Business Strategies

19.15. Other Market Participants

20. Key Findings

 

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

 

**Exclusive for Multi-User and Enterprise User.

 

At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.  

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

Research Methodology

Methodology

Key Inclusions

Methodology

Request A Sample

Ask for Discount

Enquiry Before Buying

Request For Customization

Purchase Options

Buy Now

Reach to us

Call us on

+91-74002-42424

Drop us an email at

sales@absolutemarketsinsights.com